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ABSTRACT 
The development of novel selective 5-HT6 and 5-HT7 receptor antagonists is an ever-growing area 
of interest among medicinal chemists.  The potential of developing a therapeutic agent useful as an 
antipsychotic or antidepressant, as well as the possibility to develop a drug for Alzheimer‟s disease 
and obesity has led to an increase in synthesis of possible lead compounds.  The synthesis of 
unfused biheteroaryl derivatives is described within.  The derivatives have been evaluated for 
binding affinity at 5-HT2A, 5-HT6 and 5-HT7 receptors.   
The most potent 5-HT6 receptor antagonists include a benzene ring, a hydrophobic group and a 
protonated nitrogen atom.  The most potent and selective compound synthesized is 1-[3-butyl-5-
  
(thienyl)phenyl]-4-methylpiperazine.  The binding site of the 5-HT7 receptor is similar to that of 
the 5-HT6 receptor and the most selective and potent 5-HT7 receptor antagonist also contains a 
potonated nitrogen atom and a hydrophobic group.  The difference in selectivity between the 5-
HT6 and 5-HT7 receptor antagonists is the aromatic ring.  The most potent 5-HT7 receptor 
antagonist synthesized contains a pyridine ring instead of benzene, as in the 5-HT6 receptor 
antagonist.  The most potent and selective 5-HT7 receptor antagonist is 1-[4-(3-furyl)-6-
methylpyridin-2-yl]-4-methylpiperazine.  The need to increase selectivity for both 5-HT6 and 5-
HT7 receptors has led to the synthesis of flexible-chain linked derivatives and the results are 
described within. 
   
 
INDEX WORDS: Serotonin, 5-HT7, 5-HT6, organic, heterocyclic chemistry, synthesis, benzene, 
quinazoline, pyridine, pyrimidine, biheteroaryl
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1 INTRODUCTION  
1.1 Background on Serotonin 
Serotonin (5-hydroxytryptamine; 5-HT) was discovered over 60 years ago and continues to 
generate interest as one of the most attractive and successful targets for medicinal chemists.  
Serotonin is an abundant mammalian neurotransmitter involved in numerous central nervous 
system and peripheral processes.  Page was the first to successfully isolate serotonin from blood 
serum, after which Rapport was able to identify the compound as 5-hydroxytryptamine (Figure 1).
1
  
A second line of inquiry stemmed from the histological studies of the cells present in the lining of 
the gastrointestinal tract.  Erspamer successfully isolated a substance that he called „enteramine‟ in 
1930, which he later discovered was identical to 5-hydroxytryptamine. 
2
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Figure 1. 5-Hydroxytryptamine (Serotonin, 5-HT) 
Over two decades later Twarog and Page discovered the presence of serotonin in the 
mammalian brain, which led to the discovery of serotonergic neurons and a surge in research of 
serotonin as a therapeutic target.
2
  Serotonin is an abundant neurotransmitter which elicits its 
effects by interacting with a variety of membrane bound receptors.  To date there have been 14 
serotonin receptor subtypes classified, which are grouped into 7 families (5-HT1 to 5-HT7).
1-6
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1.2 Background on 5-HT7 Receptor 
 
The most recently discovered receptor 5-HT7 was isolated simultaneously in 1993 by seven 
different research groups and has since been identified in rat, mouse, guinea pig, human and 
porcine.
4,6
  The 5-HT7 receptor was identified as a G-protein coupled receptor, having seven 
transmembrane domains.  It is positively coupled to adenylyl cyclase activity through the 
activation of the Gs proteins.
4,8 
  The exact structure of the G-protein coupled receptor is still 
unknown due to the inability to grow crystals suitable for x-ray crystallography studies.
7
  
Alternative splicing of the 5-HT7 receptor
 
gene was reported to generate different isoforms: 5-
HT7(A), (B), (C) in rat and 5-HT7(A), (B), (D) in human, that differ only in their amino acid composition 
and their carboxyl terminal tail.  Alternative splicing is a process by which the exons of the RNA 
produced by transcription of a gene are reconnected in multiple ways during RNA splicing. The 
resulting different mRNA may be translated into different protein isoforms thus, a single gene may 
code for multiple proteins.  The most abundant isoform in humans is 5-HT7A receptor, which 
consists of 445 amino acids with a long carboxy terminus.  The functions of the splice variants 
however do not differ greatly from each other.   
There are many examples of potent 5-HT7 receptor ligands that act as both agonists and 
antagonists. An agonist is a chemical that binds to a receptor and triggers a response. An agonist 
often mimics the action of a naturally occurring substance; in this case serotonin.  An antagonist is 
a chemical that binds to the receptor and elicits a reduced response or blocks the response. 
The 5-HT7 receptors are defined by their high affinity for 5-HT, 5-carboxamidotryptamine (5-
CT), methiothepin, and 5-methoxytryptamine. They also show a low affinity for pindolol, 
sumatriptan, and busprione, which are all agonists of 5-HT1A (Figure 2).
8
  The greatest abundance 
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of 5-HT7 receptor is found in the brain (thalamus, hypothalamus, limbic, and cortical regions), but 
these receptors are also found in the periphery (spleen, kidney, heart, coronary artery, and 
gastrointestinal tract).
6
  5-HT7 receptors have been associated with the control of circadian 
rhythms, sleep, depression, migraine, memory, and schizophrenia.
3-5 
 Because of the implications 
in effecting depression, 5-HT7 has become an attractive target for drug discovery and the 
identification of possible antidepressant therapeutic agents.   
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Figure 2. Compounds Known to Interact with Serotonin Receptors.  
Amisulpride (Figure 3), which is an approved drug in Italy for the treatment of schizophrenia 
has recently been reevaluated to determine the target of the drug more accurately.  It was believed 
that amisulpride targeted the dopamine receptors; D2 and D3, which allow for dopaminergic 
modulation.  After testing, however, it was discovered that amisulpride is a high potency 
competitive antagonist for the human 5-HT7A receptor.  The study was conducted on wild-type and 
5-HT7 knockout mice where the knockout mice did not respond to amisulpride in either the forced 
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swim test or the tail suspension test.  Based on these results it can be inferred that the 5-HT7A 
receptor is responsible for the antidepressant actions of amisulpride and therefore is a promising 
target for future therapeutic agents targeting antidepressant therapy.
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Figure 3. Amisulpride 
The development of a selective 5-HT7 antagonist has been challenging since the tertiary 
structure of the membrane G-protein coupled receptor is still unknown.  Because of this, many 
molecular modeling techniques have been used in order to develop a reasonable pharmacophore 
model.  3D-QSAR studies were performed in our laboratory at GSU in order to gain a better 
understanding of the 5-HT7 receptor binding site.  These QSAR studies were based on 10 
structures synthesized in our lab that showed the highest affinity for the 5-HT7 receptor.  It was 
possible to develop a pharmacophore model that displays 4 distinct features needed for selective 
binding: a H-bonding acceptor group (HBA), two hydrophobic regions (HYD2/HYD3), and a 
protonated nitrogen atom (PI, positive ion) (Figure 4).  An example of one of the compounds 
synthesized in our laboratory is shown below and the appropriate regions are labeled.  This 
compound has all four of the required binding areas present and leads to a tight binding in the 
binding site and fits the pharmacophore model proposed. 
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Figure 4. Pharmacophore Model for Selective 5-HT7 Antagonists. 
 
This pharmacophore model is very similar to previous models that have been developed, with 
one inconsistency present.  The distance calculated based on the current set of ligands between the 
protonated nitrogen atom and the hydrogen bond acceptor is calculated to be 8.7 – 9.7Å.  The 
distance reported in previously published work is between 5.6 – 6.7Å (Figure 5).10,11,16  This 
discrepancy in data may be due to the use of more flexible ligands in the previous studies, which 
would lead to an inaccurate fit into the binding site, and result in a shorter distance. 
6 
 
 
 
Figure 5. Pharmacophore model for 5-HT7 Receptor Antagonism. Taken from ref 16. 
Combining the pharmacophore model proposed from our compounds with the knowledge that 
the binding site is located along the transmembrane helix it is possible to develop ligands that are 
highly selective for the 5-HT7 receptor.  The central binding point for the ligand is a central 
asparagine amino acid.  Also present is a π-π interaction of the aromatic ring with that of 
phenylalanine in the binding pocket, or an ion-π interaction with arginine.10  The development of a 
pharmacophore model has allowed a more organized design for 5-HT7 antagonists.   
There are two classes of 5-HT7 receptor antagonists, non-selective antagonists and selective 
antagonists.  Non-selective antagonists are broken into five classes: ergolines, antipsychotic tricylic 
analogues, piperidine derivatives, aporphine derivatives, and phenylpiperazines.
11
  Ergolines, such 
as 2-Br-LSD, are effective at treating migraine, hypotension, postpartum hemorrhage and 
Parkinson‟s disease (Figure 6).11  Antipsychotic tricylic analogues such as clozapine can be 
7 
 
 
effective at treating schizophrenia, although it is assumed that both D2 and 5-HT2A help to play a 
role in the antidepressant activity of clozapine (Figure 6).
11
  Piperidine derivatives, such as 
spiperone act as both a 5-HT2 antagonist and show an affinity for the 5-HT7 receptor (Figure 6).
11
  
Aporphine derivatives, which were just recently developed by Johansson et al. have appeared to 
show moderate selectivity over 5-HT1A and dopamine D2A receptors (Figure 6).
11
  The last class of 
non-selective antagonist is that of the phenylpiperazines, such as 1-(m-chlorophenyl)piperazine 
(mCPP), which are known as the classic serotonin antagonists.  However they show low affinity 
and poor selectivity for the 5-HT7 binding site (Figure 6).
11
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Figure 6. Structures of Non-selective 5-HT7 Receptor Antagonists. 
The development of a selective 5-HT7 receptor antagonist is a somewhat more complicated 
matter.  Numerous studies have been done to gain insight into the structure of the 5-HT7 receptor 
for a more accurate development of therapeutic agents.  There have been several 5-HT7 antagonists 
synthesized and tested, but it is still a challenge to develop a highly selective ligand for this 
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receptor because there are many similarities between the binding of 5-HT1A, 5-HT2A and 5-HT7
 
receptors.  High-throughput screening was performed in 1998 by SmithKline Beecham (now 
GlaxoSmithKline) which led to the discovery of the first selective 5-HT7 antagonist, SB-258719 
(Figure 7).
11 
 This compound was selective for 5-HT7, but there was a need to increase the affinity 
for the 5-HT7 receptor.  The discovery of SB-258719 provided for an onset in the development of 
selective 5-HT7 drugs.  After modifications were made on this compound, SB-269970 was 
discovered to have high affinity and selectivity for the 5-HT7
 
receptor (Figure 7).  After in vivo 
studies however it was revealed that this compound had a high blood clearance because of the 
phenol hydroxyl group present in the molecule.  GlaxoSmithKline (GSK) has more recently 
developed compounds that are related to SB-269770 replacing of the phenol group with various 
heterocyles, and replacing the methylpiperidine ring with aromatic substituents.  GSK discovered 
that the overall affinity for 5-HT7 was reduced with the addition of the heterocyles, although SB-
656104 was discovered to have a decent affinity for the 5-HT7 receptor and showed promising 
results in vivo.  The discovery of a selective 5-HT7 receptor ligand and the development of a 
pharmacophore model have helped make the design of a novel 5-HT7 antagonist much simpler and 
the activity more predictable.  
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Figure 7. Selective 5-HT7 Receptor Antagonists. 
9 
 
 
There have been two patents filed that incorporate some of the structures that have been 
synthesized by our laboratory.  The first patent which has been filed contains four compounds that 
have been synthesized in the Strekowski laboratory; however the field of invention for the patent is 
not for 5-HT7 receptors, but instead for that of H4 histamine receptor.  The H4 histamine receptor is 
another G-coupled protein receptor, however it has different functionality than that of the serotonin 
5-HT7 receptor.
12
  The results of antagonistic activity at the H4 receptor show that the compounds 
synthesized below have a good affinity for both the H4 receptor and the 5-HT7 receptor.  This 
evidence shows how difficult it is to predict and synthesize a selective 5-HT7 antagonist.     
 
Table 1. Binding Affinity for Unfused Biheteroaryls.
a
 
N
NR
N
CH3  
ID No. R H4 Binding Ki (nM) 5-HT7 Binding Ki (nM) 
26 3-thienyl 37 79 
27 2-furyl 87 307 
28 3-furyl 25 17 
51 2-thienyl 90 396 
a
H4 data taken from ref 12. 
 
Also, it has been found that clozapine (Figure 6), which was previously mentioned as a 
nonselective antagonist for 5-HT7 is an agonist of the H4 receptor.
13
  The interaction with the H4 
receptor could be anticipated by looking at the similarity in structure of histamine and serotonin 
10 
 
 
(Figure 8).   Both molecules have an ethylamine chain off of a nitrogen containing heterocycle.  
When considering binding in the receptor site, there must be a hydrogen bond acceptor and some 
sort of hydrophobic interaction in each pocket at around the same distance from each other. This 
phenomenon would explain why similar compounds could interact with both binding sites to illicit 
a response.  The similarity between the two receptors however adds another difficulty in 
developing a selective 5-HT7 antagonist with a receptor that doesn‟t function in the same manner, 
yet has a slight affinity for compounds that act as potent 5-HT7 antagonists.   
 
N
H
NH2HO
Serotonin
N
HN
NH2
Histamine  
Figure 8. Serotonin and Histamine.  
A second patent was recently filed based on 5-HT7 receptor antagonists with pyridine 
scaffolds.
14
  Although the synthesis of the molecules is different; there is one structure that is very 
similar to those that were synthesized in Strekowski‟s laboratory.  This compound has a high 
affinity for 5-HT7 and a slight selectivity over 5-HT2A (Table 2).   Comparing compounds 
described in the patent
14
 (Table 2) with those synthesized in our laboratory (Table 3) it is found 
that similar compounds in our lab have a slightly higher affinity and selectivity over the best 
compound listed in the patent (Table 3).  
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Table 2. Selectivity of 4(3-Thienyl)pyridines Synthesized by Bojarski et al.
14
 
Structure 5-HT2a Ki (nM) 5-HT7 Ki (nM) 
NN CH3
S
N
H3C  
33 18 
NN
S
N
H3C
CH3
 
6 18 
NN
S
N
H3C
CH3
CH3
 
4 16 
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Table 3. Selectivity of Unfused Biheteroaryls Synthesized at GSU.   
Structure 5-HT2a Ki (nM) 5-HT7 Ki (nM) 
NN CH3
O
N
H3C  
62 8 
NN CH3
S
N
H3C  
115 117 
NN CH3
O
N
H3C  
445 139 
 
The activity is increased with the simple replacement of the 3-thienyl group with that of the 3-
furyl group, which can be explained because oxygen is a better hydrogen bonding acceptor group 
than sulfur, which leads to better binding in the active site and an increase in activity.  
Previously synthesized compounds in our lab have had a high affinity for the 5-HT7 receptor, 
but a low selectivity in the presence of the 5-HT2A receptor.  In order to increase the selectivity it 
was important to take into consideration the binding pocket once again.  Since the derivatives we 
synthesized were small molecules that would fit in many different binding pockets it was essential 
to expand the size of our molecule to increase the selectivity.  A previously published 
pharmacophore model suggests that there is an additional hydrophobic binding site located in 
between the PI and HYD3, and also another hydrogen bond acceptor located next to the first that 
was identified in our studies (Figure 5).
15
    
13 
 
 
Based on the additional hydrophobic site in this model it is apparent that there is a hydrophobic 
site in the binding pocket that would help increase the selectivity of the antagonist for the 5-HT7 
receptor.  Previously published work shows that the addition of linker connecting the aromatic 
region with the protonated nitrogen atom leads to an increase in selectivity for the 5-HT7 
receptor.
5,15-20
  All of the previously published work attached a linker ranging from 3 – 5 carbons in 
length connecting the heteroaryl portion to another aromatic portion (Table 4). 
Table 4. Selective 5-HT7 Antagonists. 
Structure 5-HT7 Ki (nM) 5-HT2A Ki (nM) 5-HT1A Ki (nM) 
S
O
O
H
N
O
N
N
O
 
Ref 5. 
37 5168 ---- 
N
H
O
H3C
N
N
Cl
 
Ref 19. 
0.38 ------ 11 
N
O
N
          
Ref 15. 
7±2 ------- 219±11 
14 
 
 
N
O
N
N
H
NO
F
 
Ref. 17 
2.75 302 ------ 
 
By adding a 3 – 5 carbon chain linker, the selectivity for 5-HT7 was increased significantly, as 
is evident in the table above.  This also helps provide a better pharmacophore model, since it is 
apparent that there is another small pocket for the binding of the other aromatic side chain present.  
The addition of both a spacer and a second aromatic moiety leads to a large increase in selectivity 
for the 5-HT7 receptor.  Based on that principle we synthesized a number of similar compounds 
and submitted them for biological activity. These new dimeric compounds are discussed in section 
2.5. 
 
1.3 Background on 5-HT6 Receptor 
Monsma et al.
21 
and Ruat et al. simultaneously isolated the first cDNA coding for a 5-HT6 
receptor from rat striatum in 1993.
22 
 Three years later in 1996 the human 5-HT6 receptor was 
cloned by Kohen et al. as a gene codifying a polypeptide chain of 440 amino acids, which is 
positively coupled to the adenylyl cyclase cascade via the Gs protein.
23
  The 5-HT6 receptor, like 
the 5-HT7 receptor is a G-protein coupled receptor which corresponds to a seven-transmembrane 
spanning protein.
22-23 
  The 5-HT6 receptor is mostly located in the central nervous system, however 
low levels have been detected in the stomach and adrenal glands.
21
  Within the brain the highest 
concentration is in the striatum (caudate nucleus) and low to moderate levels are found in the 
15 
 
 
nucleus accumbens, hippocampus, hypothalamus, amygdala, cerebellum and olfactory     
tubercle.
21-25
  Since 5-HT6 is mostly located in the central nervous system, it was suggested that a 
selective 5-HT6 ligand would have very few peripheral side effects.  The 5-HT6 receptor initially 
showed high affinity to numerous potent antipsychotic and antidepressant drugs, however there 
were contradictory results about the effect of the drugs on 5-HT6.  The first paper that discussed 
nonselective 5-HT6 receptor ligands discovered that tricyclic antipsychotic agents and some 
antidepressants bound to the 5-HT6 receptor with high affinity.
6
  Examples include thioridazine, 
thioxanthene chlorprothixene, amoxapine and loxapine which bound with Ki values ranging from  
3 – 15 nM (Figure 9).  However not all antipsychotics showed high affinity for 5-HT6.  Spiperone 
and haloperidol showed a much lower affinity with Ki values of 1595 nM and >5000 nM, 
respectively (Figure 9).
6
  The discovery that 5-HT6  might play a role in psychoses led to a surge in 
research, however in order to truly determine the function of the 5-HT6 receptor, a selective ligand 
had to be developed.  
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Figure 9. Nonselective 5-HT6 Receptor Antagonists.  
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In 1998 the first selective 5-HT6 receptor ligand was reported, which prompted others to 
quickly publish their work.  Sleight et al.
26
 indentified the bisaryl sulfonamides (Figure 10) as very 
selective 5-HT6 antagonists.  Shortly thereafter MS-245 and 4-bromo-N-(4-methoxy-3-(4-
methylpiperazin-1-yl)phenyl)benzenesulfonamide were published (Figure 10).
27
  Although the 
discoveries were separate the sulfonamide moiety is present in all agents.  The main reason for the 
similarity between the results of different research groups was that most of the lead compounds 
were found after high-throughput screening.  After testing the sulfonamides the major problem was 
discovered to be low CNS penetration.  This opened the door for nonsulfonamide derivatives as 
well.   
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Figure 10. 5-HT6 Antagonists. 
 
The first nonsulfonamide discovered as a potent selective 5-HT6 receptor antagonist was 5-
methoxy-2-phenyl-N,N-dimethyltryptamine (PMDT) (Figure 10).
6
  Testing was performed using 
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the newly developed selective 5-HT6 derivatives to develop a better understanding of the role of 
the 5-HT6 receptor.
6
 Some of the selective 5-HT6 ligands were tested in patients with mental 
disorders and the results were inconclusive because not all of the patients reacted to the 5-HT6 
receptor ligands that were used.  A role for 5-HT6 receptors in mental disorders could not be firmly 
established, but is still being pursued. 
The 5-HT6 receptor function has also been associated with cholinergic neurotransmission, 
which prompted interest into the possible implication of the receptor in cognitive impairment 
(learning and memory) related to neurological diseases such as Alzheimer‟s disease.25  Also, 
recently it has been shown that selective 5-HT6 ligands are able to reduce food intake, which could 
lead to a treatment for obesity, which is an ever increasing global disease that so far is an unmet 
clinical need.
27
   Right now there are a number of compounds that have entered clinical trials for 
the treatment of Alzheimer‟s disease, schizophrenia and obesity (Figure 11).25  There are currently, 
however no marketed 5-HT6 receptor ligands as therapeutic agents and the synthesis of new 
potentially useful derivates continues to be of great interest and importance.   
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Figure 11. 5-HT6 Agonists and Antagonist Currently in Clinical Trials. 
 
In hopes of making the development of more selective 5-HT6 receptor ligands simpler, it is 
important to have a better understanding of the binding pocket.  Since the 5-HT6 receptor like the 
5-HT7 receptor is a G-protein coupled receptor it is not possible to make a crystal structure, and so 
a pharmcophore model was developed based on known 5-HT6 receptor antagonists.
28
  Known 5-
HT6 antagonists (45) were used to develop a 3D pharmacophore model using HypoGen from the 
Catalyst software.
28
   It was determined from the pharmacophore model that the structural features 
needed for an antagonist to bind were a protonated nitrogen atom, which can interact with Asp, a 
hydrogen bond acceptor group which interact with Ser and Asn, a hydrophobic site interacting in a 
hydrophobic pocket and an aromatic ring hydrophobic site which interacts with Phe (Figure 12).
28
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Figure 12. 3D Phamacophore model for 5-HT6 receptor. The HYD and PI features are drawn 
as globes, whereas HBA and AR features are shown as two globes because of the directional 
nature of these chemical functions.
28
 
   
A second pharmacophore model has recently been proposed using HipHop which is also part 
of the Catalyst software.
24
  The difference between the two programs is that HipHop uses a much 
narrower scope and only looks as highly active compounds, where as HypoGen looks at a large 
range of activities and has a larger number of compounds in the study.  The following observations 
can be made by comparing the pharmacophore models below (Figure 13):  The main difference is 
the presence of the “H1” hydrophobic center in the HipHop model.  Also evident are the distances 
between the hydrophobic, aromatic ring centers and the positive ammonium group. Overall, 
however, the configuration is compatible between the two models.
24
  The hydrophobic region (H1) 
is not essential for activity, however when this region is added to the pharmacophore model it 
generated an 83% hit rate of known 5-HT6 antagonists where as the HypoGen model only recorded 
a 25% hit rate.  The HipHop model therefore would be a better model to use in order to conduct 
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high-throughput screening in hopes of generating a lead compound for the development of a 
selective 5-HT6 receptor ligand. 
 
  
Figure 13. Comparison between (a) the best HipHop pharmacophore model and (b) the 
HypoGen model.
24
  (Cyan: hydrophobic groups; green: hydrogen bond acceptor; orange: 
aromatic ring; red: positive ionizable group)
 
 
The 5-HT6 receptor is one of the more recently discovered serotonin receptors so the 
development of novel 5-HT6 receptor ligands with better pharmacokinetic and pharmacodynamic 
properties is still needed.  Since a pharmacophore model and various selective 5-HT6 antagonists 
have been identified there is more attention being paid to the function of the 5-HT6 receptors.  Now 
that there are newer 5-HT6 antagonists with better blood brain barrier penetration, it will be 
interesting to see what therapeutic potential is identified.   
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2 SYNTHESIS OF UNFUSED BIHETEROARYLS 
 
2.1 Synthesis of Substituted Pyrimidines 
 
The synthesis of pyrimidines with heteroaryl substituent at position 4 had gone unevaluated 
until the modifications made by Strekowski et al. were published.
29-31
  The earliest work focused 
on the addition of lithiated species to the pyrimidine ring, which led to the 1,6-dihydropyrimidine 
intermediate.  This intermediate was oxidized back to pyrimidine with the use of 2,3-dichloro 5,6-
dicyanobenzoquinone (DDQ) (Scheme 1).   
Scheme 1.  
N N
Cl
1. R-Li
2. H2O
N NH
H
R
Cl
DDQ
N N
Cl
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This newly developed synthesis made it possible to then add another lithiated species to the 
pyrimidine ring, leading to 4,6-disubtituted pyrimidine.  This procedure was later used to 
synthesize a number of 2,4,6-trisubstituted pyrimidines.
30-31
  After the lithium addition/substitution 
reaction was complete, an amine was used to displace the chlorine at the 2 position, which led to 
the desired products (Equation 1). 
N N
Cl
O HN N CH3
toluene
N N
N
O
N
CH3
(1)
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A similar chemistry was used to synthesize the pyrimidine ligands discussed below.  The 
organolithium reagents, 3-lithiothiophene and 2-lithiofuran were generated in THF at low 
temperature by addition of n-BuLi to 3-bromothiophene and furan respectively.
31
   After the 
lithium halogen exchange reaction (Equation 2), the corresponding organolithium reagent was used 
in situ.  A solution of 2-chloropyrimidine (1) in THF was added to the organolithium reagent at       
-78 ˚C (Scheme 2).  Once the reaction was complete, the reaction mixture was quenched with 
water/THF (1:1) and the intermediate dihydropyrimidine was rearomatized upon treatment with 
DDQ to give pyrimidines 2 and 3. 
S
Br
n-BuLi, 
THF, -78°C
S
Li
(2)
 
Addition of a ethyllithium or n-butyllithium to 2 and 3 followed by treatment with DDQ 
furnished 4,6-disubstituted pyrimidines 4 – 6 (Scheme 2).  Crude products were purified on a 
chromatotron eluting with hexanes and ether. 
The final compounds 7 – 9 were synthesized by treatment of 2-chloropyrimidines 4 – 6 with N-
methylpiperazine.  
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The preparation and use of 2-chloro-4-vinylpyrimidine (10) is shown in Scheme 3.  Thus, 
vinyllithium reagent was generated by the addition of tert-butyllithium dropwise to a solution of 
tetravinyltin in THF at -70 ˚C.  The mixture was stirred for 15 min at -70 ˚C before use.32-35   Upon 
the generation of the lithium reagent, a solution of 2-chloropyrimidine (1) in THF was added at      
-78 ˚C and the mixture was allowed to warm to -40 ˚C over 1 h (Scheme 3).  Once the reaction was 
complete, the mixture was quenched with water, and the intermediate dihydropyrimidine was 
oxidized with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ).  The crude mixture was treated with 
an aqueous solution of sodium hydroxide in order to solubilize the hydroquinone which was 
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removed with the water extraction.  Purification of the 2-chloro-4-vinylpyrimidine (10) was done 
using silica gel chromatography eluting with a mixture of hexanes and ether.  
Scheme 3. 
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As shown in Scheme 3, 2-chloro-4-vinylpyrimidine (10) undergoes a 1,4-conjugate 
nucleophilic addition across the vinyl group to give 11 – 14.  The reaction was conducted in 
toluene. 
35
  The mixture was stirred for 2 h at 90 ˚C, after which time the mixture was basified with 
aqueous sodium carbonate and extracted with ether to generate the crude products 11 – 14.  The 
crude products were used to synthesize the final products 15 – 18.  The 2-chloro substituent in 11 – 
14 was displaced with N-methylpiperazine in toluene at 80 ˚C overnight.  The mixture was basified 
with aqueous sodium carbonate and extracted with ether.
31-35 
  Purification of 15 – 18 was done on 
a chromatotron eluting with a mixture of hexanes and ether.   
The conjugate addition reaction is useful to expand the chain length and add various groups to 
the ring that otherwise would be difficult.  Simple amines undergo addition readily as do small 
alkoxide ions.  Addition of phenoxide was also attempted, but, surprisingly, there was no reaction.  
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The successful addition of ethanethiolate ion to the vinyl group of 10 should be noted. The highest 
yield (61%) was observed with the addition of benzylamine, which is a primary amine and is 
highly nucleophilic.  Dimethylamine is also a good nucleophile for this addition reaction, but the 
yield (27%) is lower.   
 
Scheme 4. 
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1,4-Conjugate addition was also performed using Grignard reagents in the presence of copper 
iodide (Scheme 4).  To a solution of copper iodide in THF was added methylmagnesium bromide 
or phenylmagnesium bromide at -50 ˚C.  The mixture was stirred for 10 min, after which a mixture 
of 2-chloro-4-vinylpyrimidine in THF was added dropwise.  The mixture was stirred to   -40 ˚C for 
2 h, and quenched with aqueous ammonium chloride to give the corresponding product 21 or 22.  
Purification was done on a chromatotron eluting with hexanes and ether.  The addition reaction 
was unsuccessful in the absence of copper iodide. 
 The reaction was attempted with a catalytic amount of copper iodide first,
36
  however, the 
yields were low (32%).  Under optimized conditions the ratio of RMgBr:CuI is 2:1.
37
  The overall 
yield for this reaction was thus increased to 70%.
38
  The increase in yield is likely a result of the 
favored 1,4-conjugate addition upon addition of copper as well as the catalytic effect of copper on 
the reaction rate.  When copper is not present the Grignard reagent does not react.
38
 Structures 21 
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and 22 are consistent with their 
1
H NMR, 
13
C NMR and high resolution mass spectra.  It is 
apparent from the absorption pattern for the propyl group on the 
1
H NMR that the addition of 
methylmagnesium bromide results in the selective addition of the methyl group to the vinyl moiety 
of compound 21.
37  
Additional evidence for selective nucleophilic addition to the vinyl group over chloride 
displacement is shown in Figure 14.  The intermediate product shown was synthesized in our 
laboratory by Ava Blake and resulted from the treatment of 10 with 0.55 equivalents of 
ethylamine.  The intermediate product, 2-(2-chloropyrimidin-4-yl)-N-(2-(2-chloropyrimidin-4-
yl)ethyl)-N-ethylethanamine was the major product isolated confirming the rate of conjugate 
addition to the vinyl group is faster than the displacement of the chloride.
37
 
 
N N
N
H3C
N N
Cl Cl  
Figure 14. 2-(2-Chloropyrimidin-4-yl)-N-(2-(2-chloropyrimidin-4-yl)ethyl)-N-
ethylethanamine. 
 
 
 
2.2 Synthesis of Substituted Quinazolines 
 
The synthesis of quinazoline derivatives has been evaluated previously for the use as selective 
5-HT7 receptor ligands, however a very different approach was taken.
38
  The quinazoline scaffold 
was used in order to develop novel receptor ligands and also confirm that the previously discussed 
1,4-conjugate nucleophilic addition reaction is not restricted to the pyrimidine scaffold.  
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A similar procedure that was used for the reaction above on pyrimidine was utilized for the 
addition of a vinyl group to the 4-position of quinazoline with slight modifications.
34 
 The 
vinyllithium addition was first attempted on commercially available quinazoline following the 
same procedure that was used for addition to the pyrimidine scaffold (Equation 3).  
 
N
N
N
N
1. Sn 
t-BuLi, THF
2.DDQ
4
X (3)
 
The vinyllithium reagent was generated by the addition of tert-butyllithium dropwise to a 
solution of tetravinyltin in THF at -70 ˚C.  The reaction mixture was stirred for 5 min at -70 ˚C 
before use.
33-35 
 Vinyllithium was then added to a solution of quinazoline in THF at -78 ˚C and the 
mixture was allowed to warm to -60 ˚C over 1 h (Equation 3).  Then, the mixture was quenched 
with water, and treated with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ).  Upon workup the 
desired 4-vinylquinazoline product was not found.  In order to determine whether the addition of 
the vinyllithium was not working or if the oxidation was the problem the presumed 
dihydroquinazoline derivative was isolated by extracting with ether.  Purification was done on a 
chromatotron eluting with hexanes, ether and methanol.  The result was the isolation of the 
dihydroquinazoline derivative, which was confirmed by 
1
H NMR.  The absorption of the NH peak 
was evident at 2.99 ppm, which confirms the dihydroquinazoline product.  Once the product was 
isolated it became apparent that the problem was the oxidation step. A previously published 
method using the milder oxidizing agent potassium ferricyanide was carried out (Scheme 5).
39
  To 
a mixture of potassium ferricyanide in aqueous saturated potassium hydroxide was added a mixture 
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of dihydroquinazoline in benzene.  The reaction mixture was stirred vigorously at room 
temperature for 1 h.  The benzene layer was extracted to give pure 4-vinylquinazoline.  
 
Scheme 5. 
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After establishing a plausible synthetic route to 4-vinylquinazoline, the synthesis of a more 
complex quinazoline was attempted.  Thus, 2,4-dichloroquinazoline was prepared as previously 
described with slight modifications to improve the yield (Scheme 6).
40
  The chlorination of 
substrate 23 (Scheme 6) was accomplished by the addition of phosphorous oxychloride in N,N-
dimethylaniline in the presence of a catalytic amount of N,N-dimethylformamide.  The mixture 
was heated for 6 h, after which it was poured over ice, and the resulting solid was filtered.  The 
crude solid was recrystallized with isopropanol to produce pure 2,4-dichloroquinazoline (24).   
The selective reduction of 2,4-dichloroquinazoline (24) to 2-chloroquinazoline (25) was 
attempted using a previously published procedure.
41
  A two-phase mixture of 24 in 
dichloromethane was covered with a solution of aqueous saturated brine which contained 9% 
ammonium hydroxide.  The mixture was treated with powdered zinc and heated under reflux.  
After workup, the product was isolated in a low yield (3%).  Different conditions were tried for the 
selective reduction in order to optimize the yield.
42 
 The experiments are described as follows. 
Bis(triphenylphosphine)palladium(II) dichloride and tributylphosphine were added to a mixture 
of 24 in dry THF.  Tributyltin hydride was added and the mixture was stirred at room temperature 
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for 5 h (Equation 4).  The mixture was concentrated and purification was done on a chromatotron 
eluting with hexanes and ether.  2-Chloroquinazoline was isolated in 17% yield, however residual 
tin remained in the product, which could not be removed.  For this reason the previously used 
biphasic system was re-examined with slight modifications to improve yield.  
N
N
Cl
Cl
(PPh3)2PdCl2, Bu3P
Bu3SnH, THF
N
N
Cl
24 25
(4)
 
The zinc that was previously used in this reaction had oxidized and was the most likely 
explanation for the low yield previously obtained in the selective reduction reaction.  In order to 
increase the yield, zinc had to be activated.  Powdered zinc was washed with hydrochloric acid 
(2%), filtered and washed again with HCl (2%), and then water, ethanol, and finally ether, and 
dried under reduced pressure to furnish activated zinc metal.  The reaction was repeated as 
specified above to give pure 2-chloroquinazoline (25) in 54% yield.  This improved yield allowed 
for the synthesis of 25 to be scaled up and the addition of the vinyllithium reagent to be attempted. 
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N
N
Cl
1) Li
N
N
N
Nu
N
Me
N NHMe
1) Nu-H (amine) or Nu-
2)
26
27-34
19-22 Nu
N N Me30
27
31
32
33
N N
Nu 23-26
28
29 34
NMe2
HN-Bun
OMe
SEt
SPhNHCH2Ph
(23-50%)
N
H
NH
O
O N
N
Cl
Cl
POCl3
N,N-dimethylaniline
DMF
23
24
CH2Cl2
9% NH3 in NaCl (sat. aq.)
Zn (dust) activated
N
N
Cl
25
2) K3Fe(CN)6, KOH
    PhH, H2O
Nu-H (amine)
or Nu-
N
N
Nu
Nu
35, 36
35 NHCH2Ph
36 N N
 
 
The conditions mentioned above for the addition of the vinyl group to quinazoline were used to 
synthesize 2-chloro-4-vinylquinazoline (26) in 68% yield (Scheme 6).  Thus, 2-chloro-4-
vinylquinazoline (26) underwent a selective 1,4-conjugate nucleophilic addition across the vinyl 
group when equimolar amounts of nucleophile and vinylquinazoline were used.  The crude 
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products then underwent a chloride displacement with N-methylpiperazine to provide products    
27 – 34 in 23 – 50% yield.  The conjugate addition reaction was selective over the chloride 
displacement reaction, however in all cases there was some addition/displacement product isolated 
after purification.  The ratio as shown in 
1
H NMR was 5:1.  The selectivity of the vinyl addition 
was generally decent, but the purification of the products proved to be challenging.  In order to 
exclusively produce the addition/displacement product three equivalents of nucelophile and one 
equivalent of 2-chloro-4-vinylquinazoline were used and products 35 and 36 were produced 
(Scheme 6).   
In order to improve the yield of the 1,4-conjugate nucleophilic addition reactions, the chloride 
displacement reaction with N-methylpiperazine was carried out before the vinyllithium reagent was 
added to quinazoline ring (Scheme 7).  The same conditions and procedures were used for the 
reaction sequence below;  the only difference is the order of the reaction sequence which led to an 
increase in yield and simplified purification.  Also, in this case the nucleophile can be added in 
excess because there is no possibility for the double reaction.  This reaction sequence resulted in 
increased yields of the overall synthesis to 50 – 63%.  Although there is selectivity in the conjugate 
addition reaction over the chloride displacement reaction the overall process in synthesizing 
derivatives was easier through this route because a large amount of the intermediate 2-(4-
methylpiperazino)-4-vinylquinazoline (38) could be synthesized and only one step was needed to 
synthesize final products.   
Selectivity for nucleophilic conjugate addition to the vinyl group can be confirmed by 
comparing the identical products isolated from the two separate schemes.  The products that are 
isolated are confirmed by 
1
H NMR, 
13
C and high-resolution mass spectrometry.  The higher yields 
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for the products in Scheme 7 can be explained by the simplification in purification that results from 
fewer side products (Table 5).  
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Table 5. Yields from Scheme 6 and Scheme 7. 
Compound # Yield (Scheme 6) Yield (Scheme 7) 
27 27% 50% 
28 31% 55% 
29 50% 62% 
30 40% 53% 
31 23% 50% 
32 27% 52% 
33 35% 54% 
34 50% 63% 
 
The synthesis of 4-(3-furyl)-2-(4-methylpiperazino)quinazoline (40) is given in Scheme 8. The 
organolithium reagent, 3-lithiofuran, was generated in THF at low temperature by addition of n-
BuLi to 3-bromofuran as previously described (Equation 2).
31
  The organolithium reagent was used 
in situ for the reaction with 2-chloroquinazoline (25) in THF at -78 ˚C (Scheme 8).  Once the 
reaction was complete as shown by TLC analysis, the reaction mixture was quenched with 
water/THF (1:1) and the intermediate dihydroquinazoline was rearomatized upon the addition of 
DDQ.  Purification was done on a chromatotron eluting with hexanes and ethyl acetate to provide 
2-chloro-4-(furan-3-yl)quinazoline (39).  A simple chloride displacement was done to provide the 
final product 40 in 69% yield.  The oxidation with DDQ was successful, which was surprising, but 
could be because the vinyl moiety used previously is more reactive than the furan ring.  DDQ 
could have resulted in side reactions with the vinyl group that would not be possible with the furan 
ring, allowing in this case a successful rearomatization.  
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Quinazoline derivatives were also synthesized starting from 2,4-dichloroquinazoline through a 
chloride displacement reaction that was accomplished the same as previously discussed (Scheme 
9).  This reaction led to a mixture of mono (41) and disubstituted (42) products in 31% and 18% 
yield respectively.  The mono-substituted product underwent a second chloride displacement with 
N-phenylpiperazine to provide 43 in 27% yield. It is known that 2,4-dichloroquinazoline reacts 
regioselectively at the 4-position in a variety of reactions; the difference in reactivity was utilized 
in order to selectively give the desired compound 41.
43
  The difference in reactivity can be 
explained by the stabilizing influence of the resonance forms of 4-chloroquinazoline over those of 
2-chloroquinazoline (Figure 15).
44
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Figure 15. Resonance Structures of 4-Chloroquinazoline and 2-Chloroquinazoline. 
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2.3 Synthesis of Substituted Benzenes 
 
Coupling reactions are one of the most commonly used methods to form new carbon-carbon 
bonds with a benzene ring.
43, 45-48
 Palladium cross-coupling reactions are used widely by medicinal 
chemists to synthesize the desired products.
43
   
The first step in the synthesis of 2,4-disubstituted and 2,4,6-trisubstituted benzenes was 
accomplished through a Buchwald-Hartwig amination. This reaction was first reported in the mid-
1980‟s and couples amines to aryl halides in the presence of palladium or nickel catalysts.43  This 
reaction was first used in academic settings for the use in natural product total synthesis, and in 
industry for the preparation of materials on a kilogram scale.
44
 The general mechanism for this 
reaction is well understood and follows a palladium catalytic cycle (Figure 16).  Although this 
procedure was developed a number of years ago it was still necessary to test various conditions in 
order to develop a method that would lead to monoaddition to the dibromo-substituted benzene 
ring.   
 
37 
 
 
LnPd 
(0)
Ar X
oxidative 
addition
LnPd 
(II)
X
Ar
LnPd 
(II)
O
Ar
tBu
LnPd 
(II)
X
Ar
HNR2
LnPd 
(II)
NR2
Ar
M Ot-Bu
M Ot-Bu
M X
HOt-Bu
+ MX
HNR2
HOt-Bu
Ar-NR2
reductive 
elimination
HNR2
 
Figure 16. Palladium Catalytic Cycle for Buchwald-Hartwig Amination. 
The starting material, 1,3-dibromo-5-butylbenzene (46) is not commercially available, but can 
be synthesized easily (Scheme 10).
46
  N-Bromosuccinimide dissolved in N,N-dimethylformamide 
was added to a solution of 4-butylaniline in N,N-dimethylformamide at 0 °C dropwise.  The 
reaction mixture was stirred at 0 °C for 3 h, and concentrated.  The crude residue was purified 
using a plug of silica gel eluting with hexanes and concentrated to provide a 2,6-dibromo-4-
butylbenzamine (45, Scheme 10).  The Sandmeyer reaction was used to synthesize 1,3-dibromo-5-
butylbenzene (46).  2,6-Dibromo-4-butylbenzeneamine in ethanol and sulfuric acid were combined 
and heated to 75 °C.  Sodium nitrite was added in small portions and the mixture was allowed to 
stir at 75 °C for 2 h.  Ice water was added and the reaction was extracted with dichloromethane and 
concentrated.  The crude residue was purified on a chromatotron eluting with hexanes.  Thus, 1,3-
dibromo-5-butylbenzene (46) was generated in a 50% overall yield.  After the synthesis of 46, a 
palladium-cross coupling reaction could be attempted and the conditions could be optimized. 
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The first set of conditions included 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) as 
the ligand, tris(dibenzylideneacetone)dipalladium(0) (Pd2dba3) as the palladium catalyst and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as a base and sodium tert-butoxide to help initiate the 
reaction (Scheme 11).
47
  These conditions were used to synthesize 50 giving a low yield of 27% 
(Scheme 11).  1,3-dibromobenzene (47) was combined with BINAP, Pd2dba3 and DBU and N-
methylpiperazne in toluene.  The mixture was heated to 60 ˚C and sodium tert-butoxide (few 
crystals) was added.  The mixture was refluxed overnight.  After workup the crude product was 
provided.  Since the yield (27%) was not decent, new conditions were tried. 
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The catalyst and ligand were kept constant however DBU was no longer used.  Instead, only 
sodium tert-butoxide was used as a base.
43
  All of the reagents were combined in a round bottom 
flask and the mixture was heated under reflux overnight.  The mixture was filtered over Celite, and 
concentrated to provide a crude residue.  The residue was purified on a chromatotron to improve 
the yield to 54%.  The yield could be improved further by changing either the catalyst of ligand to 
determine which conditions are the best for this reaction sequence, but it was not necessary for this 
synthesis because enough intermediate was synthesized easily for this two step synthesis.   
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The second step of this reaction sequence is a Suzuki coupling reactions.  Also, in this instance 
it was important to try difference conditions to find one that worked well. A Suzuki reaction 
involves the coupling of an aryl boronic acid and an aryl halide to form a new carbon-carbon bond.   
The first method used a mixture of 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex and potassium phosphate in 1,4-dioxane 
(Scheme 11).
47
  A mixture of boronic acid, 50, 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex and potassium phosphate were combined in 1,4-
dioxane.  The reaction stirred at 100 °C over 7 days, after which it was filtered and extracted with 
dichloromethane.  The crude residues were purified on a chromatotron eluting with hexanes and 
ether to give 52 – 58.  The reaction time was too long for this method to be useful and new 
conditions were needed. 
A mixture of 3-thienylboronic acid, 1-(3-bromophenyl)-4-methylpiperazine (50), 
tetrakis(triphenylphosphine)palladium and potassium carbonate in 1,4-dioxane and water were 
combined and the mixture was stirred at 100 °C for 5 days.
48,49
  The mixture was filtered through 
Celite and concentrated.  The mixture was purified on chromatotron eluting with hexanes, ether 
and methanol to provide 61 in 23% yield. The solubility of the reagents seemed to be poor, so a 
new solvent was needed to further increase the yield. 
The third set of conditions tried were similar to the second tried only instead of using 1,4-
dioxane as a solvent, N,N-dimethylformamide was used and the reaction was carried out in a sealed 
tube in hopes of decreasing the reaction time necessary for the reaction to go to completion.  The 
same protocol was followed as stated above.  A mixture of boronic acid, 1-(3-bromophenyl)-4-
methylpiperazine (50), tetrakis(triphenylphosphine)palladium and potassium carbonate in N,N-
dimethylformamide and water were combined in a sealed tube and the mixture was stirred at 80 °C 
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overnight.
48,49
  The mixture was filtered, dichloromethane and water were added, and the organic 
layer was washed with water in order to remove DMF.  The crude products were purified on a 
chromatotron eluting with hexanes, ether and methanol to provide pure products in 12 – 76% yield.  
The low yields were seen when coupling 2-substituted boronic acids and the highest yields were 
seen when coupling 3-subsituted boronic acids.   
Both the Buchwald-Hartwig and the Suzuki reaction are well known reactions in which the 
conditions can be further optimized for individual derivatives if needed by altering ligand, catalyst, 
base or solvent. 
The previously optimized protocols for each reaction were used in the next synthesis of 1,4-
didubstituted benzenes (Scheme 12).  The Buchwald-Hartwig reaction was used to couple 1,4-
dibromobenzene with N-methylpiperazine in 46% yield.  Then the coupling of 67 with aryl boronic 
acids under the conditions used above provides the final products 68 – 69.   
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68-69  
 1-(3,5-Di(3-furyl)phenyl)-4-methylpiperazine (72) was also synthesized following the 
similar coupling procedures.  The only difference in the synthesis is that 2.5 equivalents of 3-
furanboronic acid was used to 1.0 equivalent of 71.  The final product 72 was isolated in 4% yield 
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(Scheme 13).  Compound 72 was synthesized to ensure that work previously published in our lab 
based on 5-HT2A was correct and that a symmetrical compound would not have a good affinity for 
5-HT7 receptor.
29 
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The benzene compound 74 was prepared in a similar manner.  However, instead of using N-
methylpiperazine, N-benzylpiperazine was utilized.  Compound 74 was synthesized by a Suzuki 
coupling of 73 with 3-furanboronic acid (Scheme 14). 
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The preparation of benzene derivatives was important to determine if a nitrogen was essential 
in the ring system for there to be activity in the 5-HT receptor binding site.  
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2.4 Synthesis of Substituted Pyridines 
 
Pyridine is one of the most commonly used heterocyclic compounds for both agrochemicals 
and pharmaceuticals.
50
 It has previously been noted that pyridine is a good scaffold for the 
synthesis of 5-HT7 receptor antagonists.
14
  The synthesis of the previously synthesized pyridines 
was done in a cyclization reaction, and was limited in the substitutents that could be used.  The 
synthesis that was used in our lab started with a ring system already intact and coupling reactions 
were conducted in order to add various substituents.  The synthesis of substituted pyridines is 
similar to the synthesis of the previously discussed benzene derivatives.  It is slightly more 
challenging however to construct the pyridine ring system so that coupling reactions can be 
completed.    
The synthesis begins with 4-hydroxy-6-methyl-2H-pyran-2-one (75) by treatment with 
ammonium hydroxide in ethanol at 130 ˚C for 24 h (Scheme 15).  The mixture is then concentrated 
to dryness to provide 76 in >99% yield.
51 
 This reaction is very useful for converting a pyranone to 
a pyridinone.  
The next step is a bromination reaction with phosphorous tribromide.
52-54
  Compound 76 is 
combined with 1.3 equivalents phosphorous tribromide in a sealed tube at 190 ˚C for 5 h.  The 
mixture is poured over ice-water and allowed to stand overnight at room temperature.  The solution 
is extracted with dichloromethane and concentrated to provide 2,4-dibromo-6-methylpyridine (77) 
in 9% yield.  Since the yield was low, bromination was attempted by treatment of 76 with 
phosphorous oxybromide (Scheme 15). 
55
 
4-Hydroxy-6-methylpyridin-2(1H)-one (76) was combined with toluene and 4.0 equivalents of 
phosphourous oxybromide was added to the solution.  The mixture was heated under reflux for 5 h, 
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then poured over ice-water and basified with aqueous saturated sodium hydroxide.  The aqueous 
layer was extracted with ethyl acetate and concentrated.  This procedure resulted in a mixture of 
starting material and product based on 
1
H NMR.  Although the yield for the reaction with 
phosphorous tribromide was low, it worked and resulted in clean product without the need of 
purification, so it was utilized in the synthesis of the pyridine substituted derivatives. 
 
Scheme 15. 
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The next two steps in the synthesis are identical to those that were used in the synthesis of the 
benzene derivatives.  First, a Buchwald-Hartwig amination reaction is done with N-
methylpiperazine and 2,4-dibromo-6-methylpyridine (77).  N-Methylpiperazine, 77, BINAP, 
sodium tert-butoxide, Pd2dba3, and toluene are combined in a sealed tube and the mixture was 
stirred at 80 ˚C overnight.  The mixture was filtered through celite, washed with ethyl acetate and 
concentrated to provide crude 1-(4-bromo-6-methylpyridin-2-yl)-4-methylpiperazine (78).  The 
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residue was purified on a chromatotron eluting with hexanes, ether and methanol to provide 78 in 
8% yield (Scheme 15). This yield is extremely low, but enough starting material was generated 
after this reaction to complete the synthesis so optimization of these conditions was not necessary.  
If this synthesis needed to be repeated however different conditions would have to be looked at. 
The last step in the synthesis of substituted pyridine rings in a Suzuki coupling reaction.  A 
mixture of 1-(4-bromo-6-methylpyridin-2-yl)-4-methylpiperazine (78), a boronic acid, Pd(PPh3)4, 
potassium carbonate, DMF and water in a sealed tube was heated at 90 ˚C overnight.  The mixture 
was filtered through Celite™, washed with ethyl acetate and concentrated.  The residue was 
purified on a chromatotron eluting with hexanes, ether and methanol to provide 79 - 81 in 4-31% 
yield (Scheme 15).  
The next set of compounds synthesized is similar to the discussed pyridines.  The difference is 
that the methyl group is in the 4-position instead of the 2-position.  Commercially available 4-
methylpyridine-2,6-diol (82) undergoes bromination with phosphorous tribromide to prepare 2,6-
dibromo-4-methylpyridine (83) in 16% yield (Scheme 16).  1-(6-Bromo-4-methylpyridin-2-yl)-4-
methylpiperazine (84) is synthesized under the previously discussed Buchwald-Hartwig conditions 
in 26% yield.  Lastly, compounds 85 – 87 are prepared through a Suzuki coupling reaction in 16 – 
32% yield. 
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2.5 Synthesis of Flexible-Chain Linked Derivatives 
 
Starting from previously reported 5-HT7 receptor agonists and antagonists we synthesized a 
series of compounds intending to increase the selectivity for the 5-HT7 receptor.  There have been 
very few selective 5-HT7 antagonists synthesized.
4, 5, 15, 17, 19, 56
  Table 4 shows the most selective 5-
HT7 antagonists.  The few that have been the most selective over the other 5-HT receptors all 
contain a hydrophobic chain linked to a separate aromatic compound containing a hydrogen bond 
acceptor group.
15
  We synthesized a series of compounds by joining benzene and pyridine 
derivative previously synthesized in our lab, with parts of known selective 5-HT7 antagonists 
previously synthesized.
15,18,57
  The three linkers that were chosen were done so based on ease of 
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synthesis and the expected affinity to the binding pocket.  We chose 1-(4-bromobutyl)indolin-2-
one, 4-bromobutyl phenylsulfone, and 6-bromo-N-(4-cyanobenzyl)hexanamide.
15,18,57 
1-Boc-piperazine (88) was synthesized as a starting material for used in the procedures to 
follow.
58 
 Piperazine in dichloromethane was cooled to 0 ˚C, treated with di-tert-butyl dicarbonate 
dissolved in dichloromethane and the mixture was stirred at 0 ˚C for 2 h and then warmed to room 
temperature for 24 h.  The precipitate was filtered, dissolved in water, and the aqueous solution 
was basified with potassium carbonate, extracted with ether and concentrated to give 1-Boc-
piperazine 88 (Equation 5).  
N NH
O
O
88
HN NH
Boc2O, DCM, 0 °C - rt
piperazine
(5)
 
3,5-Dibromotoluene (48) or 2,6-dibromopyridine (89) were combined with 1-Boc-piperazine 
(88), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, tris(dibenzylideneacetone)dipalladium(0) and 
sodium tert-butoxide in toluene in a sealed tube and heated to 90 °C overnight.  The mixture was 
filtered over Celite™, washed with EtOAc and concentrated to prepare compounds 90 and 91 
(Scheme 17).   
Compounds 90 and 91 then undergo a Suzuki coupling with 3-furanboronic acid through the 
same procedure discussed previously for synthesis of benzene derivatives.  A mixture of 3-
furanboronic acid, 90 and 91, tetrakis(triphenylphosphine)palladium and potassium carbonate in 
N,N-dimethylformamide and water were combined in a sealed tube and stirred at 80 °C overnight.   
The mixture was filtered through Celite™ and washed with ethyl acetate. The filtrate was washed 
with water and concentrated.  The crude residue was purified on a chromatotron eluting with 
hexanes and ether to provide 92 and 93 (Scheme 17).   
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Products 92 and 93 were deprotected using trifluoroactice acid in dichloromethane.  The 
mixture was stirred for 1 h at room temperature, after which the mixture was concentrated to give 
94 and 95 (Scheme 17). 
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4-Bromo-2-chloropyridine (96) was combined with 3-furanboronic acid, 
tetrakis(triphenylphosphine)palladium and potassium carbonate in N,N-dimethylformamide and 
water in a sealed tube and the mixture was stirred at 90 °C overnight.   The mixture was filtered 
through Celite™ and washed with ethyl acetate. The filtrate was washed with water and 
concentrated.  The crude residue was purified on a chromatotron eluting with hexanes and ether to 
provide 2-chloro-4-(furan-3-yl)pyridine (97) (Scheme 18).   
49 
 
 
Excess 1-Boc-piperazine (88) was added to a solution of 2-chloro-4-(furan-3-yl)pyridine (97) 
in toluene and the mixture stirred overnight at 90 °C.  The mixture was concentrated to prepare 
compound 98 (Scheme 18).   
Deprotection of the amino group was accomplished by reacting 98 in dichloromethane with 
trifluoroacetic acid.  The mixture was concentrated, basified with aqueous saturated sodium 
bicarbonate and extracted with dichloromethane to prepare a crude residue. The residue was 
purified on a chromatotron eluting with hexanes, ether and methanol to provide 1-[4-(3-
furyl)pyridin-2-yl]piperazine (99, Scheme 18).  
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The piperazine function of compounds 94 , 95 and 99 was alkylated with various alkyl halide 
derivatives that were synthesized by Jeffrey Klenc by known synthetic procedures.
15,18,57
 
Compounds 94 , 95 and 99 were dissolved in acetonitrile, and the appropriate bromoalkyl 
derivative was added, followed by the addition of triethylamine.  The mixture was stirred at 60 ˚C 
overnight.
15
  The mixture was then concentrated and dissolved in dichloromethane.  The solution 
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was washed with water and then concentrated.  The crude residue was purified on a chromatotron 
eluting with hexanes, ether and methanol to prepare compounds 100 – 108 in 15 – 44 % yield 
(Scheme 19). 
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Compounds 100 – 102 were synthesized based on previously described literature.18  The 
cyanobenzyl hexamide derivative that was described with the best affinity and selectivity (Figure 
17) was modified based on previously synthesized compounds which showed good affinity from 
our studies.  Previously reported data showed that five methylene units separating the amide 
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moiety and the piperazine ring were preferred over other chain lengths.
18
  It was also discovered 
that the position and the nature of the substituent on the phenyl ring linked to the piperazine ring 
was critical; shifting the substituent from the 2-position to the 3- or 4- position resulted in loss of 
affinity.  The piperazine moieties used in our studies have substituents at the 4-position, however 
we are also adding a nitrogen to the phenyl substituent in the form of 2,4- and 2,6-substituted 
pyridine rings.  The effect of the pyridine ring is thus far unknown, however compounds have been 
sent to our collaborator for evaluation of binding affinity.   
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Figure 17. Most Selective N-(4-cyanobenzyl)hexamide Derivative.
15
 
 
Compounds 103 – 105 were also synthesized based on previously published work.57 
Aminoalkyl phenyl sulfones were discovered to be possible 5-HT7 receptor antagonists through 
molecular modeling studies which showed an overlap with SB-269970 (Figure 18), which as 
discussed previously is a known 5-HT7 antagonist.  The gem-dimethyl sulfone was coupled with 
various piperazine and piperadine molecules to generate a small library of compounds, in which 
the most selective is shown in Figure 16.  Testing showed that this compound had an excellent 
selectivity (> 100 fold) over the other receptors tested.  It was also revealed that substitution at the 
3-position of the amine moiety showed attenuation of functional activity without a decrease in 
selectivity. The compounds synthesized in our lab are substituted at the 4-position.  Such 
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compounds were not described in this paper 
57
, so the affinity and selectivity of our compounds is 
yet unknown. 
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Figure 18. Sulfone With Highest Affinity and Selectivity.
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The synthesis of compounds 106 – 108 was also based on the previously published work.18 The 
published paper described a series of oxindole derivatives in order to develop a pharmacophore 
model which was based on highly selective 5-HT7 receptor antagonists.  This study led to the 
development of a pharmacophore model that can be used for high throughput screening in order to 
generate a lead target for drug synthesis.  The most potent derivative (Figure 19) had a high 
selectivity and affinity.  It was shown that by extending the alkyl chain to five methylene groups, 
the selectivity for 5-HT7 over 5-HT1A  was decreased leading to the use of a 4 carbon chain linker, 
which resulted in increased selectivity for the 5-HT7 receptor.  Using a monocyclic ring structure, 
such as in Figure 18 rather than a bicyclic system in Figure 19 leads to poor affinity for 5-HT1A 
which is preferred.   
N
O
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Figure 19. Most Potent Oxindole Derivative.
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3 BIOLOGICAL ACTIVITY 
 
The compounds that were prepared as described above were submitted for biological testing 
against the 5-HT2A, 5-HT7 and 5-HT6 receptors, and the results are shown in Table 6.  The 
biological assays were conducted by Bojarski et al. at the Institute of Pharmacology, Polish 
Academy of Sciences and were performed as previously described.
59,60
   
 
Table 6. Structure and binding data for 5-HT2A, 5-HT6 and 5-HT7 antagonists. 
ID 
number 
Structure 
5-HT2A Ki 
(nM) 
5-HT7 Ki 
(nM) 
5-HT6 Ki 
(nM) 
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251 380 508 
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N
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7 15 ----- 
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3.1 5-HT7 and 5-HT6 Selective Ligands 
 
The studies in our laboratory previously focused on 5-HT1A and 5-HT2A receptors; however, 
the discovery of the 5-HT7 receptor led to the interest in this area as well. 
Previous structure-activity relationship analysis was performed for the 5-HT2A receptor ligands 
and it was indicated that pyrimidines containing 2-thienyl and 3-furyl groups have the highest 
affinity for the 5-HT2A receptor.
60
  The pyrimidine compounds synthesized were however not 
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selective for the 5-HT2A receptor, but also had a high affinity to the 5-HT7 receptor.   Based on 
these findings it was necessary to determine if the rigidity of the furan ring was indeed what 
allowed for such high affinity to both the 5-HT2A and 5-HT7 receptors.  Compound 17 (Table 6) 
was synthesized in order to test these findings and the data shows that when the rigidity of the 
furan ring is taken away so is the affinity for the receptors.  When compound 17 is compared with 
the affinity of compound 8 it is apparent that the rigidity of the furan ring increases the affinity by 
ten fold over that of the flexible ether in compound 17. 
Also, compounds 7 – 9 were synthesized to complete the set that had previously been 
synthesized in our lab.  Compound 9 showed high affinity for both the 5-HT2A receptor and 5-HT7 
receptor, however there was no selectivity.  
A series of quinazoline derivatives was tested as well, all which show poor affinity for the 5-
HT2A, 5-HT6 and 5-HT7 receptors.  Only compound 36 appears to show affinity for 5-HT7 and it 
also shows 100 fold selectivity over the other two receptors tested.  Compound 36 is much bulkier 
than the others synthesized and contains two phenyl-piperazine groups.  These groups could 
interact with the two different hydrophobic binding areas better than the rest that were synthesized.  
Most of the other species that were tested are aliphatic chains containing a heteroatom which if not 
placed in the right part of the binding pocket could lead to repulsion and poor affinity.   
Benzene derivatives were then synthesized to determine whether a nitrogen containing 
heterocycle was needed for the ligand to retain affinity for the binding pocket.  The biological data 
shows that the benzene ligands still have affinity for the receptor.  By looking at the biological data 
it is evident that when a hydrogen or methyl group is present on the scaffold (52, 57) there is a 
higher affinity for the 5-HT7 receptor than for the 5-HT6 receptor.  However when the methyl 
group is extended to a butyl group (61 – 63), the selectivity for the 5-HT6 receptor is 100 fold 
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greater than for 5-HT2A or 5-HT7.  These are important starting points for the development of a 
highly selective 5-HT6 or 5-HT7 receptor antagonist.   
The pyridines that were tested showed high affinity for all three receptors tested, therefore they 
are not selective ligands. 
Testing was also done on the flexible-chain linked derivatives in hopes of increasing 
selectivity.  
4 CONCLUSION 
 
Since the discovery of serotonin (5-HT) over 60 years ago the search for therapeutic agents 
targeting the HT receptors has been ever-growing.  The discovery of 5-HT7 receptor in 1993 led to 
a surge in research to determine the function of the receptor.  Once this receptor was determined to 
be associated with sleep, depression, migraine, memory and schizophrenia the development of a 
therapeutic agent targeting one of these areas was underway.  The 5-HT6 receptor was discovered 
directly before the 5-HT7 receptor however less in known about the 5-HT6 receptor.  The 5-HT6 
receptor has been associated with Alzheimer‟s disease, obesity, and psychosis.  The discovery of a 
drug that selectively targets the 5-HT6 receptor could result in a breakthrough in research and the 
first real treatment for Alzheimer‟s disease. 
The synthesis of numerous scaffolds based on the many pharmacophore models available for 
both the 5-HT6 and 5-HT7 receptors has led to the development of some novel highly selective 
compounds.  The synthesis of numerous potential receptor ligands has led to a better understanding 
of what it necessary to develop a selective 5-HT7 or 5-HT6 receptor antagonist. 
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Our laboratory has synthesized hundreds of pyrimidines compounds for testing against 5-HT2A, 
5-HT1A and 5-HT7 receptors.  The result was the development of new chemistry through the 
addition of a lithiated species to the pyrimidine ring followed by oxidation with DDQ.
29-31
  The 
extension to that work was the addition of vinyllithium to the pyrimidine ring. 2-Chloro-4-
vinylpyrimidine (10) then underwent 1,4-conjugate addition in order to yield another variety of 
compounds for testing.  Quinazoline derivatives were then tested to see if this chemistry could be 
duplicated.   
Benzenes and pyridines were next derivatized because of recently published patents that 
showed high selectivity for 5-HT7 with pyridine.  Benzene was looked at because it was questioned 
whether a nitrogen was necessary in the aromatic ring to retain affinity.  The biological activity 
shows that nitrogen is not necessary, however without nitrogen there is a high selectivity for 5-HT6 
over 5-HT7.   
Lastly, the synthesis of flexible-chain linked derivatives will help to determine whether a 
longer and therefore more complex structure is necessary for increase selectivity for the 5-HT7 and 
5-HT6 receptors. 
 
4.1 Future Work 
 
The search for a selective 5-HT7 receptor antagonist continues to be a major area of interest 
among medicinal chemists.  There are numerous pharmacophore models that have been proposed 
and based on those it appears there are six key interactions that are necessary to have high affinity 
and selectivity: two H-bonding acceptor groups (green) , three hydrophobic regions (blue), and a 
protonated nitrogen (red) (Figure 5).     
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There is a hydrophobic site in the binding pocket that could help increase the selectivity of the 
antagonist for the 5-HT7 receptor.  Previously published work shows that the addition of a flexible-
chain linked aromatic region leads to an increase in selectivity for the 5-HT7 receptor.
5,15-20
  All of 
the previously published work attached a linker ranging from 3-5 carbons in length connecting the 
heteroarene portion to another aromatic portion (Table 4). 
By adding a 3 – 5 carbon chain linker, the selectivity for 5-HT7 was increased significantly, as 
is evident from Table 4.  The spacer has not been modified in order to explore the possibilities of 
the binding in the hydrophobic region.  It would be informative to make derivatives with 
cyclopropane to cylcohexane rings installed in the linker (Figure 20).  Also in order to increase the 
solubility in plasma which needs to be taken into account, the use of a polyethylene glycol linker 
could be attempted.  It would be useful to determine how nonpolar the linker has to be or if there 
are amino acids present that could interact with the oxygen present in the polyethylene glycol 
moiety (Figure 20).  This has yet to be explored and could lead to interactions that would lead to a 
more selective 5-HT7 antagonist.   
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Figure 20. Examples for Future Synthesis. 
Also modifiying the previously synthesized compounds in our lab with the addition of long 
alkyl chains with the addition of simple amines or thiols should be investigated also (Figure 21).  
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Figure 21. Alkyl Chain Derivatives for Future Work. 
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5 EXPERIMENTAL 
5.1 General 
 
THF was purified by distillation from sodium benzophenone ketyl under a nitrogen atmosphere.  
All reagents were purchased from a commercial source and used as received. Glassware was dried 
in an oven at 120 ˚C, assembled hot and cooled to room temperature under a continuous nitrogen 
flow prior to use.  Hydrobromide salts of the piperazine products were obtained by using the 
general procedure, 
30,34 
and the salts were crystallized from methanol.  In several cases it was 
necessary to dilute the methanolic solution with ether to induce crystallization.  GC/MS spectra 
were obtained on a Shimadzu GC-17A gas chromatotron coupled to a Shimadzu QP-5000 mass 
spectrometer at 70 eV.  NMR data were obtained in CDCl3 at 27 ˚C on a Bruker instrument (400 
MHz) and elemental analysis was obtained on a Perkin Elmer 2400 Series II CHN analyzer.  
Melting points are uncorrected. Intermediates that were not sent for analysis of biological activity 
were not fully characterized.  Final products were fully characterized by 
1
H NMR, 
13
C NMR, 
accurate mass, and elemental analysis.  Radioligand binding studies for the 5-HT2A, 5-HT7 and 5-
HT6 receptors were performed according to the published procedure.
59 
 
5.2 Lithium Reagents 
 
n-Butyllithium (2.5 M in hexanes) and tert-butyllithium (1.7 M in pentane) were commercial 
reagents.  3-Lithiothiophene was generated by lithium halogen exchange reaction between 3-
bromothiophene and n-butyllithium.
34
 A solution of the corresponding bromo derivative (12.5 
mmol) in anhydrous THF (15 mL) was cooled to -70 ˚C and treated dropwise with n-butyllithium 
(6.3 mL, 12.6 mmol) for 5 min.  The mixture was stirred at -70 ˚C for 30 min before treatment with 
2-chloropyrimidine.  2-Lithiofuran was generated by lithiation of furan.
34
  Vinyllithiuim was 
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generated by the reaction of tetravinyltin with tert-butyllithium as previously described.
60-63
 A 
solution of tetravinyltin (0.7 mL, 3.2 mmol) in tetrahydrofuran (5.0 mL), was treated dropwise 
with tert-butyllithium (7.4 mL, 12.6 mmol) at -78 ˚C for 5 min, and the mixture was stirred for an 
additional 15 min at -78 ˚C before use. 
 
5.3 Synthesis of Pyrimidines 
 
General procedure for synthesis of 4,6-substituted 2-(4-methylpiperazino)pyrimidines 7 – 9.  
Compounds 7 – 9 were prepared as previously described with slight modifications.30,61  A solution 
2-furyllithium or 3-thienyllithium (8.7 mmol) in THF (5.0 mL) was treated dropwise with 2-
chloropyrimidine (1.0 g, 8.7 mmol) in tetrahydrofuran (30 mL) at -5 °C under nitrogen 
atmosphere.  The mixture was stirred for 30 min at -5 °C, then quenched with water (5.0 mL) in 
tetrahydrofuran (5.0 mL).  After treatment with 2,3-dichloro-5,6-dicyanoquinone (DDQ, 1.9 g, 8.7 
mmol), the reaction solution stirred for 5 min to reach room temperature.  The solution was 
basified with sodium carbonate (saturated) till pH = 9 and was then extracted with diethyl ether (2 
× 30 mL), dried over magnesium sulfate, and concentrated in vacuo to provide a crude residue.  
The crude residue was purified by chromatography eluting with hexanes/diethyl ether (80:20) to 
provide 2 and 3 which were utilized in the next step.  A solution of either ethyllithium or n-
butyllithium (1.2 mmol) was added dropwise to a solution of 2 or 3 (1.1 mmol) in tetrahydrofuran 
(3.0 mL) at -78 °C.  The reaction solution stirred for 5 min, then quenched with water (1.0 mL) in 
tetrahydrofuran (1.0 mL) and allowed to warm to room temperature.  After treatment with 2,3-
dichloro-5,6-dicyanoquinone (DDQ, 1.1 g, 8.7 mmol), the reaction solution was allowed to stir for 
5 min to reach room temperature.  The solution was basified with sodium carbonate (saturated) till 
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pH = 9 and was then extracted with diethyl ether (2 × 20 mL), dried over magnesium sulfate, and 
concentrated in vacuo to provide crude residue.   The crude residue was purified by 
chromatography eluting with hexanes/diethyl ether (80:20) to provide 4 – 6 which were utilized for 
the reaction with N-methylpiperazine.  A solution of compound 4 – 6 (179 mg, 0.75 mmol) and N-
methylpiperazine (0.25 mL, 2.26 mmol) in toluene (3.0 mL) was heated to 80 °C overnight, after 
which the mixture was cooled to room temperature.  The reaction mixture was basified with 
sodium carbonate, extracted with Et2O (2 × 15 mL), dried (MgSO4), filtered and concentrated in 
vacuo.  The crude residue was purified on a chromatotron with EMD 60PF254 silica gel eluting 
with dichloromethane/methanol (100:0 for 100 mL, then 9:1 for 250 mL) to provide 7 – 9.  
2-Chloro-4-(2-furyl)pyrimidine (2, EAR-II-56): This compound was obtained as a white solid in 
56 % yield (884 mg), mp 57 – 59 °C.  1H NMR (CDCl3, 400 MHz): δ 8.56 (d, J = 4.8 Hz, 1H), 
7.63 (s, 1H), 7.52 (d, J = 5.2 Hz, 1H), 7.38 (d, J = 3.6 Hz, 1H), 6.61 (t, J = 1.6 Hz, 1H); 
13
C NMR 
(CDCl3, 400 MHz):  δ 161.8, 159.9, 158.1, 150.6, 146.3, 114.6, 113.2, 113.1;  High-resolution ms 
(ESI, positive ion mode): calcd. for C8H5ClN2O (M + 1)
+
, m/z 181.0162; Found m/z 181.0169.  
Anal Calcd. for C8H6ClN2O: C, 53.21; H, 2.79; N, 15.51. Found: C, 53.61; H, 2.26; N, 15.48. 
2-Chloro-4-(3-thienyl)pyrimidine (3, EAR-II-66(5)): This compound was obtained as a white 
solid 14% yield (123 mg), mp = 58 – 60 °C.  1H NMR (CDCl3, 400 MHz): δ 8.59 (d, J = 5.2 Hz, 
1H), 8.22–8.21 (m, 1H), 7.69 (dd, J = 4.8 Hz, 1.2 Hz, 1H), 7.47 (d, J = 5.4 Hz, 1H), 7.45–7.43 (m, 
1H). Anal Calcd. for C8H5ClN2S: C, 47.90; H, 2.26; N, 13.24. Found: C, 48.20; H, 2.56; N, 12.98. 
2-Chloro-4-ethyl-6-(2-furyl)pyrimidine (4, EAR-II-60). This compound was obtained as a white 
solid in 55% yield (96 mg), mp 28 – 30 °C.  1H NMR (CDCl3, 400 MHz): δ 7.61 (s, 1H), 7.40 (s, 
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1H), 7.35 (d, J = 3.6 Hz, 1H), 6.59–6.58 (m, 1H), 2.81 (q, J = 7.6 Hz, 2H), 1.34 (t, J = 7.6 Hz, 3H);  
13
C NMR (CDCl3, 400 MHz):  δ 175.9, 161.2, 157.8, 150.7, 145.6, 115.6, 112.8, 110.77, 30.9, 
12.7;  High-resolution ms (ESI, positive ion mode): calcd. for C10H9ClN2O (M + 1)
+
, m/z 
209.0476; Found m/z 209.0482. 
4-Butyl-2-chloro-6-(2-furyl)pyrimidine (5, EAR-II-58).   This compound was obtained as a 
white solid in 73% yield, (190 mg); mp 30 – 33 °C.  1H NMR (CDCl3, 400 MHz): δ 7.63 (s, 1H), 
7.40 (s, 1H), 7.36 (d, J = 3.6 Hz, 1H), 6.61–6.60 (m, 1H), 2.79 (t, J = 8.0 Hz, 2H), 1.80–1.72 (m, 
2H), 1.48–1.39 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 400 MHz):  δ 175.2, 157.8, 
150.9, 145.8, 114.1, 113.0, 111.9, 93.5, 37.8, 31.1, 22.6, 14.0;  High-resolution ms (ESI, positive 
ion mode): calcd. for C12H13ClN2O (M + 1)
+
, m/z 237.0795; Found m/z 237.0795. 
4-Butyl-2-chloro-6-(3-thienyl)pyrimidine (6, EAR-II-67). This compound was obtained as a 
clear colorless oil in 76% yield (53 mg).  
1
H NMR (CDCl3, 400 MHz): δ 8.18–8.17 (m, 1H), 7.67 
(dd, J = 5.2 Hz, 1.2 Hz, 1H), 7.43–7.41 (m, 1H), 7.30 (s, 1H), 2.77 (t, J = 8.0 Hz, 2H), 1.78–1.71 
(m, 2H), 1.46–1.37 (m, 2H), 0.96 (t, J = 7.2 Hz, 3H).  
4-Ethyl-6-(2-furyl)-2-(4-methylpiperazino)pyrimidine (7, EAR-II-62).  This compound was 
obtained as a clear colorless oil in 61% yield (63 mg).  
1
H NMR (CDCl3, 400 MHz): δ 7.52 (s, 
1H), 7.12 (d, J = 3.2 Hz, 1H), 6.77 (s, 1H), 6.51–6.50 (m, 1H), 3.91 (t, J = 4.8 Hz, 4H), 2.64 (q, J = 
7.4 Hz, 2H), 2.48 (t, J = 4.8 Hz, 4H), 2.34 (s, 3H), 1.27 (t, J = 7.4 Hz, 3H); 
13
C NMR (CDCl3, 400 
MHz):  δ 173.2, 162.0, 155.8, 153.3, 144.1, 112.1, 110.8, 102.4, 55.3, 46.5, 43.8, 31.4, 12.7;  High-
resolution ms (ESI, positive ion mode): calcd. for C15H20N4O (M + 1)
+
, m/z 273.1725; Found m/z 
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273.1715.  A hydrobromide salt, mp > 250 °C; Anal Calcd. for C15H20N4O•2HBr: C, 41.50; H, 
5.11; N, 12.70. Found: C, 41.79; H, 4.87; N, 12.28. 
4-Butyl-6-(furyl)-2-(4-methylpiperazino)pyrimidine (8, EAR-II-59(2)).  This compound was 
obtained as clear colorless oil in 78% yield (178 mg).   
1
H NMR (CDCl3, 400 MHz): δ 7.52 (s, 
1H), 7.11 (d, J = 3.2 Hz, 1H), 6.75 (s, 1H), 6.52–6.50 (m, 1H), 3.90 (t, J = 4.6 Hz, 4H), 2.60 (t, J = 
7.4 Hz, 2H), 2.48 (t, J = 4.6 Hz, 4H), 2.34 (s, 3H), 1.74–1.66 (m, 2H), 1.42–1.37 (m, 2H), 0.94 (t, J 
= 7.4 Hz, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 172.4, 162.1, 155.8, 153.4, 144.1, 112.2, 110.8, 
103.1, 55.3, 46.5, 43.9, 38.1, 30.8, 22.7, 14.2;  High-resolution ms (ESI, positive ion mode): calcd. 
for C17H24N4O (M + 1)
+
, m/z 301.2026; Found m/z 301.2028.  A hydrobromide salt, mp 183–185 
°C; Anal Calcd. for C17H24N4O•HBr: C, 53.55; H, 6.61; N, 14.10. Found: C, 53.34; H, 6.60; N, 
14.69. 
4-Butyl-2-(4-methylpiperazino)-6-(thiophen-3-yl)pyrimidine (9, EAR-II-69(2)).  This 
compound was obtained as a white solid in 11% yield (6.3 mg), mp 33 – 35 °C.  1H NMR (CDCl3, 
400 MHz): δ 8.00 (bs, 1H), 7.63 (d, J = 5.2 Hz, 1H), 7.36–7.34 (m, 1H), 6.67 (s, 1H), 3.93 (bs, 
4H), 2.60 (t, J = 7.4 Hz, 2H), 2.49 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H), 1.74–1.66 (m, 2H), 1.43–1.37 
(m, 2H), 0.94 (t, J = 7.4 Hz, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 172.3, 159.9, 141.7, 126.4, 
126.2, 125.6, 104.9, 91.2, 55.3, 46.5, 43.9, 38.1, 30.9, 22.7, 14.2;  High-resolution ms (ESI, 
positive ion mode): calcd. for C17H24N4S (M + 1)
+
, m/z 317.1800; Found m/z 317.1800.  Anal 
Calcd. for C17H24N4S, H2O: C, 64.81; H, 7.74; N, 16.30. Found: C, 64.41; H, 7.83; N, 16.70. 
2-Chloro-4-vinylpyrimidine (10, EAR-I-137). This compound was synthesized according to 
previously published work.
34
  The 
1
H NMR spectrum of 10 [(CDCl3) δ 8.57 (d, J = 5.0 Hz, 1H), 
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7.22 (d, J = 5.0 Hz, 1H), 6.70 (m, 1H), 6.52 (m, 1H), 5.80 (m, 1H)] was virtually identical with that 
reported in literature for the compound obtained by an independent route.
47   13
C NMR (CDCl3):  δ 
165.5, 161.6, 159.9, 133.9, 125.3, 116.5; High-resolution ms (ESI, positive ion mode): calcd. for 
C6H5ClN2 (M + 1)
+
, m/z 141.0218; found m/z 141.0220. 
General procedure for the synthesis of 15 -18.  To a mixture of 2-chloro-4-vinylpyrimidine 
(0.115 g, 1.0 mmol) in toluene (5.0 mL) was added the corresponding nucleophile (dimethylamine, 
benzylamine, methoxide or ethane thiolate) (0.14 g, 1.0 mmol).  The mixture was stirred at room 
temperature overnight or at 90 °C for 2 h, then cooled to room temperature, basified with sodium 
carbonate and extracted with ethyl ether (2 × 15 mL).  The organic extracts were combined, dried 
over magnesium sulfate, and concentrated in vacuo to provide crude 2-chloro-4-substituted 
pyrimidine derivatives 11 – 14, that without further purification were used for the reaction with N-
methylpiperazine.  Thus, a solution of crude compounds 11 – 14 and N-methylpiperazine (0.14 
mL, 1.2 mmol) in toluene (4.0 mL) was heated to 80 °C until a TLC analysis on silica gel eluting 
with hexanes/ethyl ether (80:20) showed the absence of 11 – 14 (several hours).  The solution was 
cooled to room temperature, basified with sodium carbonate and extracted with ethyl ether (2 × 15 
mL).  The organic extracts were combined, dried over magnesium sulfate, and concentrated in 
vacuo to provide crude compounds 15 – 18.  The crude products were purified on a chromatotron 
with normal phase EMD 60PF254 silica gel eluting with hexanes/ethyl ether/methanol (80:15:5) to 
give 15 – 18. 
2-(2-Chloropyrimidin-4-yl)-N,N-dimethylethanamine (11, EAR-I-47(2)).  This compound was 
obtained as a light yellow oil in 27% yield.  Product decomposed when put on silica gel for 
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purification.  
1
H NMR (CDCl3, 400 MHz): δ 8.52 (d, J = 5.2 Hz, 1H), 7.21 (d, J = 5.2 Hz, 1H), 
2.95 (t, J = 7.2 Hz, 2H), 2.75 (t, J = 7.6 Hz, 2H), 2.34 (s, 6H). 
N,N-Dimethyl-2(2-(4-methylpiperazino)pyrimidin-4-yl)ethanamine (15, EAR-I-53(2)). This 
compound was obtained as a brown oil in 55% yield;  
1
H NMR (CDCl3):  δ 8.20 (d, J = 4.8 Hz, 
1H), 6.41 (d, J = 4.8 Hz, 1H), 3.86 (t, J = 5.2 Hz, 4H), 2.77–2.74 (m, 2H), 2.71–2.69 (m, 2H), 2.48 
(t, J = 5.2 Hz, 4H), 2.35 (s, 3H), 2.31 (s, 6H); 
13
C NMR (CDCl3): δ 169.2, 161.7, 157.4, 109.4, 
57.9, 54.9, 46.2, 45.2, 43.6, 35.7.  High-resolution MS (ESI, positive ion mode): calcd. for 
C13H23N5 (M
+
 + 1), m/z 250.2007; found m/z 250.2032. 
N-Benzyl-2-(2-chloropyrimidin-4-yl)ethanamine (12, EAR-I-35(4)). This compound was 
obtained as a light yellow oil in 61% yield (268 mg).   
1
H NMR (CDCl3):  δ 8.51 (d, J = 5.2 Hz, 
1H), 7.34–7.27(m, 5H), 7.17 (d, J = 4.8 Hz, 1H), 3.83 (s, 2H), 3.09 (d, J = 6.8 Hz, 2H),  2.99 (t, J = 
6.4 Hz, 2H). 
N-Benzyl-2-(2-(4-methylpiperazino)pyrimidin-4-yl)ethanamine hydrobromide (16, EAR-I-
40).  This salt was obtained in 62% yield; mp 110–112 °C;   1H NMR (DMSO-d6): δ 10.0 (bs, 1H), 
8.96 (bs, 1H), 8.37 (d, J = 4.8 Hz, 1H), 7.58–7.55 (m, 2H), 7.49–7.42 (m, 3H), 6.73 (d, J = 5.4 Hz, 
1H), 4.68 (d, J = 14.4 Hz, 2H), 4.24 (t, J = 5.4 Hz, 2H), 3.55–3.50 (m, 2H), 3.39–3.29 (m, 4H), 
3.06 (t, J = 7.6 Hz, 4H), 2.86 (bs, 3H); 
13
C NMR (CDCl3): δ 169.0, 161.6, 157.6, 129.1, 128.5, 
128.3, 127.3, 109.4, 54.9, 53.6, 47.4, 46.2, 43.6, 36.8;  MS (ESI) m/z 312 (M
+
 + H).  Anal. Calcd 
for C18H25N5•4HBr•H2O: C, 33.10; H, 4.78; N, 10.72.  Found: C, 33.43; H, 5.10; N, 10.66. 
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2-Chloro-4-(2-methoxyethyl)pyrimidine (13, EAR-I-39). This compound was obtained as a light 
yellow oil in 58% yield (63 mg).  
1
H NMR (CDCl3):  δ 8.53 (d, J = 4.8 Hz, 1H), 7.23 (d, J = 5.2 
Hz, 1H), 3.79 (t, J = 6.4 Hz, 2H), 3.36 (s, 3H), 3.03 (t, J = 6.0 Hz, 2H). 
4-(2-Methoxyethyl)-2-4-methylpiperazino)pyrimidine (17, EAR-I-55).  The free base was 
obtained as an oil in 55% yield;  
1
H NMR for the free base (CDCl3):  δ 8.22 (d, J = 5.0 Hz, 1H), 
6.44 (d, J = 5.0 Hz, 1H), 3.87 (t, J = 5.0 Hz, 4H), 3.77 (t, J = 6.8 Hz, 2H), 3.37 (s, 3H), 2.85 (t, J = 
6.8 Hz, 2H), 2.48 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H); 
13
C NMR (CDCl3): δ 168.1, 161.7, 157.4, 109.4, 
70.9, 58.7, 55.0, 46.2, 43.6, 38.0.  High-resolution MS for the free base (ESI, positive ion mode): 
calcd. for C12H20 N4O (M
+
+ 1), m/z 237.1705; found m/z 237.1715. The hydrobromide salt was 
obtained as a brown solid; mp 114–116 °C.   Anal. calcd for: calcd for C12H20N4O •3HBr: C, 30.09; 
H, 4.24; N, 11.70.  Found: C, 29.86; H, 4.34; N, 12.12. 
2-Chloro-4-(2-(ethylthio)ethyl)pyrimidine (14, EAR-I-32(3)).  This compound was obtained as 
a light yellow oil in 20% yield (69 mg).  
1
H NMR (CDCl3, 400 MHz):  δ 8.53 (d, J = 4.8 Hz, 1H), 
7.16 (d, J = 4.8 Hz, 1H), 3.07 (t, J = 6.6 Hz, 2H), 2.96 (t, J = 6.6 Hz, 2H), 2.58 (q, J = 7.4 Hz, 2H), 
1.27 (t, J= 7.4 Hz, 3H).   
4-(2-(Ethylthio)ethyl)-2-(4-methylpiperazino)pyrimidine (18, EAR-I-46(1)).  This compound 
was obtained as an oil in 25% yield;  
1
H NMR (CDCl3):  δ 8.22 (d, J = 5.0 Hz, 1H), 6.41 (d, J = 5.0 
Hz, 1H), 3.87 (t, J = 4.8 Hz, 4H), 2.92–2.90 (m, 2H), 2.88–2.86 (m, 2H), 2.60 (q, J = 7.4 Hz, 2H), 
2.49 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H), 1.29 (t, J = 7.4 Hz, 3H); 
13
C NMR (CDCl3):  δ 168.9, 161.7, 
157.4, 109.1, 55.0, 46.2, 43.6, 38.0, 29.8, 26.0, 14.7.  High-resolution MS (ESI, positive ion 
mode): calcd. for C13H22N4S (M
+
+ 1), m/z 267.1632; found m/z 267.1643. 
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General procedure for the synthesis of 21 and 22. To a solution of copper iodide (0.03 g, 0.18 
mmol) in tetrahydrofuran (2.0 mL) was added Grignard reagent (3.0 M in hexanes, 0.32 mL, 0.96 
mmol) at -50 °C.  The mixture was stirred for 10 min, after which compound 10 (100 mg, 0.71 
mmol) in tetrahydrofuran (4.0 mL) was added dropwise.  The mixture was stirred to -40 °C over 2 
h, quenched with saturated aqueous NH4Cl.  The mixture was extracted with ethyl acetate (2 × 15 
mL); the organic layers were combined, dried over magnesium sulfate, and concentrated on a 
rotary evaporator to provide crude 19 and 20.  Without further purification, 19 and 20 were used 
for the reaction with N-methylpiperazine.  Thus, a solution of crude 19 and 20 and N-
methylpiperazine (0.04 mL, 0.33 mmol) in toluene (3.0 mL) was heated to 120 °C until TLC 
analysis showed the absence of 19 and 20 (several hours).  The mixture was cooled to room 
temperature, basified with sodium carbonate, and extracted with diethyl ether (2 × 10 mL).  The 
organic layers were combined, dried over magnesium sulfate and concentrated in vacuo.  The 
residues were purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/ethyl 
ether/methanol (80:15:5) to provide 21 and 22.  
2-Chloro-4-propylpyrimidine (19, EAR-I-126).  This compound was obtained as a light yellow 
oil in 55% yield (28 mg).   
1
H NMR (CDCl3, 400 MHz): δ   8.51 (d, J = 5.2 Hz, 1H), 7.13 (d, J = 
5.2 Hz, 1H), 2.75 (t, J = 7.6 Hz, 2H), 1.81–1.74 (m, 2H), 1.00 (t, J = 7.6 Hz, 3H). 
2-(4-Methylpiperazino)-4-propylpyrimidine (21, EAR-I-128).  This compound was obtained as 
an oil in 56% yield;
  1
H NMR (CDCl3):  δ 8.22 (d, J = 5.2 Hz, 1H), 6.46 (d, J = 5.2 Hz, 1H), 4.67 
(d, J = 14.0 Hz, 2H), 3.96 (t, J = 14.0 Hz, 2H), 3.36–3.25 (m, 7H), 2.56 (t, J = 7.6 Hz, 2H), 1.75–
1.70 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H);  
13
C NMR (CDCl3): δ 170.2, 160.3, 157.3, 110.0, 65.8, 60.5, 
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39.8, 38.6, 21.6, 13.8.  High-resolution MS (ESI, positive ion mode): calcd. for C12H20 N4 (M
+
 + 
1), m/z 220.1700; found m/z 220.1706. 
2-Chloro-4-phenethylpyrimidine (20, EAR-I-86(2)).  This compound was obtained as a light 
yellow oil in 32% yield (125 mg). 
1
H NMR (CDCl3, 400 MHz): δ   8.47 (d, J = 4.8 Hz, 1H), 7.32–
7.28 (m, 2H), 7.23–7.10 m, 3H), 7.02 (d, J = 4.8 Hz, 1H), 3.07 (t, J = 9.2 Hz, 4H).    
2-(4-Methylpiperazino)-4-phenethylpyrimidine (22, EAR-I-87).  This compound was obtained 
as an oil in 77% yield;  
1
H NMR (CDCl3): δ 8.19 (d, J = 5.0 Hz, 1H), 7.31 (t, J = 7.2 Hz, 2H), 
7.23–7.21 (m, 3H), 6.35 (d, J = 5.0 Hz, 1H), 3.88 (t, J = 4.8 Hz, 4H), 3.04 (q, J = 7.2 Hz, 2H), 2.90 
(q, J = 7.2 Hz, 2H), 2.49 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H);  
13
C NMR (CDCl3): δ 170.0, 161.7, 
157.3, 141.4, 128.4, 128.3, 125.9, 109.0, 55.0, 46.3, 43.6, 39.4, 34.2.  High-resolution MS (ESI, 
positive ion mode): calcd. for C17H22N4 (M
+
 + 1), m/z 283.1931; found m/z 283.1923. 
5.4 Synthesis of Quinazolines 
2,4-Dichloroquinazoline (24, EAR-II-45):  2,4-dichloroquinazoline was prepared as previously 
described
40
 with slight modifications to improve the yield.  Benzoyleneurea (5.0 g, 30.8 mmol), 
phosphorus oxychloride (14.9 mL, 163.4 mmol), N,N-dimethylaniline (1.6 mL, 12.3 mmol) and 
N,N-dimethylformamide (2 drops) were combined in a round bottom flask under nitrogen 
atmosphere.  The mixture was heated to 120° C for 6 h, after which the reaction was cooled to 
room temperature, and poured over ice.  The mixture was filtered, washed with water (300 mL) 
and dried under reduced pressure at room temperature overnight. The pink solid was crystallized 
with i-PrOH (50 mL) to provide 2,4-dichloroquinazoline (24, 2.95 g, 48%) as an off-white solid,  
mp 64–66 °C.  1H NMR (CDCl3, 400 MHz):  δ 8.31 (d, J = 8.4 Hz, 1H), 8.03 (t, J = 4.4 Hz, 2H), 
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7.79–7.75 (m, 1H);  13C NMR (DMSO- d6, 400 MHz) δ 162.8, 150.3, 140.8, 134.9, 126.9, 122.3, 
115.3, 114.3. 
2-Chloroquinazoline (25, EAR-I-138): 2-Chloroquinazoline was prepared as previously 
described.
40
 2,4-Dichloroquinazoline (24, 1.0 g, 5.00 mmol) was combined with CH2Cl2 (20 mL) 
in a round bottom flask.  A solution of 9% NH3 in a saturated aqueous solution of NaCl (20 mL) 
was added to the mixture followed by activated Zn (dust, 32 mesh) (980 mg, 15.0 mmol).  The 
mixture was vigorously stirred for 5 h at 40° C under nitrogen atmosphere.  The mixture was then 
cooled to room temperature and filtered through Celite washing with CH2Cl2 (20 mL).  The 
organic layer was washed with aqueous hydrochloric acid (1.0 N, 20 mL), dried (Na2SO4), filtered 
and concentrated in vacuo.  The solid was purified on a chromatotron with EMD 60PF254 silica gel 
eluting with hexanes/ethyl acetate (4:1 for 100 mL, then 1:1 for 100 mL) to provide 2-
chloroquinazoline (25, 443 mg, 54%) as a yellow solid.  
1
H NMR (CDCl3, 400 MHz): δ 9.33 (s, 
1H), 8.04–7.97 (m, 3H), 7.74–7.70 (m, 1H). 
2-Chloro-4-vinylquinazoline (26, EAR-II-9).   2-Chloro-4-vinylquinazoline was prepared 
according to Babbitt.
39 
 tert-Butyllithium (3.70 mL, 6.30 mmol) was added to a solution of 
tetravinyltin (0.84 mL, 4.62 mmol) in tetrahydrofuran (10.0 mL) at -78 °C.  The reaction mixture 
was stirred for 5 min at -78 °C until a cloudy white suspension formed, after which a solution of 2-
chloroquinazoline (25, 960 mg, 4.20 mmol) in tetrahydrofuran (7.0 mL) was added dropwise.   The 
mixture was allowed to warm to -60 °C slowly over 1 h, after which the reaction was quenched 
dropwise with a mixture of water (2.0 mL) and tetrahydrofuran (2.0 mL).  The mixture was 
allowed to warm to room temperature, then basified with aqueous sodium carbonate until the pH = 
9,  extracted with Et2O (2 × 30 mL), dried (MgSO4), filtered and concentrated in vacuo to provide 
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a crude yellow solid of 2-chloro-4-vinyl-3,4-dihydroquinazoline  (85 mg, 0.44 mmol).  A solution 
of this product dissolved in benzene (2.0 mL) was added to a solution of potassium hydroxide 
(0.079 g, 1.41 mmol), potassium ferricyanide (III) (0.350 g, 1.05 mmol) in water (0.50 mL) under 
nitrogen atmosphere at room temperature.  The mixture was stirred vigorously for 5 h, after which 
benzene (20 mL) and water (20 mL) were added and the organic layer was extracted, dried 
(MgSO4), filtered and concentrated in vacuo to provide 2-chloro-4-vinylquinazoline (26, 57 mg, 
68%) as a off-white solid; mp 65 – 67 °C.  1H NMR (CDCl3, 400 MHz):  δ 8.21 (d, J = 8.4 Hz, 
1H), 8.01 (d, J = 4.8 Hz, 1H), 7.94 (t, J = 7.2 Hz, 1H), 7.68 (t, J = 5.6 Hz, 1H), 7.59–7.52 (m, 1H), 
6.97 (dd, J = 9.2, 1.6 Hz, 1H), 6.02 (dd, J = 9.2, 1.6 Hz, 1H).  
13
C NMR (CDCl3, 400 MHz):  δ 
165.5, 157.8, 153.2, 135.0, 129.2, 128.4, 128.2, 128.1, 124.6, 121.4.  High-resolution ms (ESI, 
positive ion mode): calcd. for C10H7ClN2 (M
+
 + 1), m/z 190.0379; found m/z 190.0376. Anal. 
Calcd. for C10H7ClN2: C, 63.01; H, 3.70; N, 14.70. Found: C, 62.64; H, 3.55; N, 15.00. 
General procedure for the synthesis of 4-substitued-2-(4-methylpiperazino)quinazolines 27 – 
34.  To a mixture of 2-chloro-4-vinylquinazoline (26, 0.15g, 0.78 mmol) in toluene (3.0 mL) was 
added the corresponding nucleophile (0.12 g, 0.78 mmol).  The mixture was stirred at 90 °C for 2 
h.   The mixture was cooled to room temperature, basified with sodium carbonate and extracted 
with ethyl ether (2 × 15 mL).  The organic extracts were combined, dried over magnesium sulfate, 
and concentrated in vacuo to provide crude 4-substituted 2-chloroquinazolines that without further 
purification were used for the reaction with N-methylpiperazine.  Thus, solutions of crude 
compounds and N-methylpiperazine (0.30 mL, 2.7 mmol) in toluene (3.0 mL) were heated to 80 
°C until a TLC analysis on silica gel eluting with hexanes/ethyl ether/methanol (80:15:5) showed 
the absence of intermediates (several hours).  The solution was cooled to room temperature, 
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basified with sodium carbonate, and extracted with ethyl ether (2 × 15 mL).  The organic extracts 
were combined, dried over magnesium sulfate, and concentrated in vacuo to provide crude 
compounds 27 – 34.  The crude products were purified by chromatotron with EMD 60PF254 silica 
gel eluting with hexanes/ethyl ether/methanol (50:40:10) to give 27 – 34. 
N,N-Dimethyl-2-[2-(4-methylpiperazino)quinazolin-4-yl]ethanamine (27, EAR-II-27).  The 
free base was obtained as a yellow oil in 27% yield;  
1
H NMR for the free base (CDCl3):  δ 7.86 (d, 
J = 8.0 Hz, 1H), 7.60–7.57 (m, 2H), 7.18 (t, J = 7.2 Hz, 1H), 3.99 (t, J = 5.0 Hz, 4H), 3.29 (t, J = 
7.2 Hz, 2H), 2.85 (t, J = 8.0 Hz, 2H), 2.51 (t, J = 5.0 Hz, 4H), 2.36 (s, 6H), 2.35 (s, 3H);  
13
C NMR 
for the free base (CDCl3):  δ 170.1, 158.4, 152.3, 133.3, 126.4, 124.6, 122.1, 118.6, 57.6, 55.1, 
46.3, 45.5, 43.8, 32.4.  High-resolution MS (ESI, positive ion mode): calcd. for C17H25N5 (M
+
 + 1), 
m/z 300.2175; found m/z 300.2188.  A hydrobromide salt: mp 100 – 106 °C (dec.). Anal. Calcd. for 
C17H25N5•3.5HBr•H2O: C, 34.00; H, 5.12; N, 11.66. Found: C, 33.74; H, 5.40; N, 11.26. 
N-[2-(2-(4-Methylpiperazino)quinazolin-4-yl)ethyl]butanamine (28, EAR-II-37(2)).  The free 
base was obtained as a brown oil in 31% yield;  
1
H NMR for the free base (CDCl3):  δ 7.83 (d, J = 
8.0 Hz, 1H), 7.62–7.53 (m, 2H), 7.14 (d, J = 8.0 Hz, 1H), 3.96 (s, 4H), 3.49 (t, J = 6.6 Hz, 2H), 
3.30 (t, J = 6.6 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 2.51 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H), 1.64–1.59 
(m, 3H), 1.40–1.32 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H);  13C NMR for the free base (CDCl3):  δ 
169.1, 158.3, 152.5, 133.8, 126.6, 124.7, 122.6, 118.6, 55.2, 49.3, 46.8, 46.4, 44.1, 32.5, 31.2, 20.6, 
14.0;  High-resolution MS (ESI, positive ion mode): calcd. for C19H29N5 (M
+
 + 1), m/z 328.2503; 
found m/z 328.2501. A hydrobromide salt: mp 153 – 155 °C.  Anal. Calcd. for 
C19H29N5•3HBr•3H2O: C, 36.04; H, 6.21; N, 11.06. Found: C, 35.89; H, 6.00; N, 11.28. 
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N-Benzyl-2-[2-(4-methylpiperazino)quinazolin-4-yl]ethanamine (29, EAR-II-57).  The free 
base was obtained as a yellow oil in 50% yield;  
1
H NMR for the free base (CDCl3):  δ 7.84 (d, J = 
8.0 Hz, 1H), 7.64–7.56 (m, 2H), 7.33 (d, J = 4.4 Hz, 4H), 7.28–7.25 (m, 1H), 7.18 (t, J = 8.0 Hz, 
1H), 3.96 (d, J = 4.6 Hz, 4H), 3.88 (s, 2H), 3.38 (t, J = 6.2 Hz, 2H), 3.22 (t, J = 6.2 Hz, 2H), 2.49 
(t, J = 4.6 Hz, 4H), 2.36 (s, 3H), 2.26 (bs, 1H);  
13
C NMR for the free base (CDCl3):  δ 170.1, 
158.4, 152.4, 140.2, 133.6, 128.6, 128.3, 127.2, 126.5, 124.7, 122.4, 118.8, 55.2, 54.2, 46.7, 46.4, 
44.0, 33.7.  High-resolution MS (ESI, positive ion mode): calcd. for C22H27N5 (M
+
 + 1), m/z 
362.2354; found m/z 362.2345.  A hydrobromide salt: mp  160 – 162 °C.   Anal. Calcd. for 
C22H27N5•3HBr: C, 43.73; H, 5.00; N, 11.59. Found: C, 43.88; H, 5.48; N, 11.39. 
2-(4-Methylpiperazin-1-yl)-4-[2-(4-methylpiperazino)]quinazoline (30, EAR-I-139).   This 
compound was obtained as  a brown solid in 40% yield; mp 72–74 °C;  1H NMR (CDCl3):  δ 7.88 
(d, J = 7.6 Hz, 1H), 7.63–7.57 (m, 2H), 7.22–7.18 (m, 1H), 4.00 (t, J = 8.0 Hz, 4H), 3.37–3.32 (m, 
2H), 2.98–2.94 (m, 2H), 2.66 (bs, 4H),  2.52 (t, J = 4.8 Hz, 8H), 2.37 (s, 3H), 2.33 (s, 3H);   Anal. 
Calcd. for C20H30N6: C, 67.76; H, 8.53; N, 23.71. Found: C, 67.93; H, 8.84; N, 23.96. 
2-(4-Methylpiperazin-1-yl)-4-[2-(4-phenylpiperazino)ethyl]quinazoline (31, EAR-II-20).  The 
free base was obtained as a brown oil in 23% yield; 
1
H NMR for the free base (CDCl3):  δ 7.90 (d, 
J = 8.0 Hz, 1H), 7.66–7.58 (m, 2H), 7.31–7.27 (m, 2H), 7.21 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 8.0 
Hz, 2H), 6.88 (t, J = 7.2 Hz, 1H), 4.03 (s, 4H), 3.39 (t, J = 7.8 Hz, 2H), 3.27 (t, J = 4.8 Hz, 4H), 
3.02 (t, J = 7.8 Hz, 2H), 2.79 (t, J = 4.8 Hz, 4H), 2.55 (t, J = 6.0 Hz, 4H), 2.39 (s, 3H);  
13
C NMR 
for the free base (CDCl3):  δ 170.2, 159.3, 152.5, 151.4, 133.6, 129.3, 126.7, 124.8, 122.5, 119.9, 
118.8, 116.3, 56.6, 55.2, 53.4, 49.3, 46.3, 43.9, 31.9.  High-resolution MS (ESI, positive ion 
mode): calcd. for C25H32N6 (M
+
 + 1), m/z 417.2751; found m/z 417.2767.  A hydrobromide salt: 
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mp  190 – 194 °C (dec.).   Anal. Calcd. for C25H32N6•4HBr•2H2O: C, 38.68; H, 5.19; N, 10.83. 
Found: C, 38.78; H, 5.51; N, 10.46. 
4-(2-Methoxyethyl)-2-(4-methylpiperazino)quinazoline (32, EAR-II-24).  This compound was 
obtained as  a yellow solid in 27% yield; mp 35–37 °C;  1H NMR (CDCl3):  δ 7.86 (d, J = 8.0 Hz, 
1H), 7.61–7.55 (m, 2H), 7.18 (t, J = 8.0 Hz, 1H), 3.99 (t, J = 4.8 Hz, 4H), 3.94 (t, J = 7.2 Hz, 2H), 
3.41–3.38 (m, 5H), 2.51 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H);  13C NMR (CDCl3): δ 168.9, 158.4, 
152.3, 133.4, 126.4, 124.7, 122.2, 118.8, 70.5, 58.8, 55.1, 46.3, 43.8, 34.1.  High-resolution MS 
(ESI, positive ion mode): calcd. for C16H22N4O (M
+
 + 1), m/z 287.1874; Found m/z 287.1872.  
Anal. Calcd. for C16H22N4O: C, 67.11; H, 7.74; N, 19.56. Found: C, 67.33; H, 8.05; N, 19.22. 
4-(2-(Ethylthio)ethyl)-2-(4-methylpiperazino)quinazoline (33, EAR-II-26).  This compound 
was obtained as a yellow solid in 35% yield; mp 38–40 °C;  1H NMR (CDCl3):  δ 7.83 (d, J = 8.0 
Hz, 1H), 7.63–7.55 (m, 2H), 7.18 (t, J = 7.0 Hz, 1H), 4.00 (t, J = 4.8 Hz, 4H), 3.41 (t, J = 7.0 Hz, 
2H),  3.07 (t, J = 8.0 Hz, 2H), 2.63 (q, J = 7.0 Hz, 2H), 2.51 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H), 1.30 
(t, J = 8.0 Hz, 3H); 
13
C NMR (CDCl3):  δ 169.8, 158.6, 152.5, 133.6, 126.6, 124.6, 122.4, 118.6, 
55.3, 46.5, 44.0, 34.6, 29.3, 26.4, 15.0.  High-resolution MS (ESI, positive ion mode): calcd. for 
C17H24N4S (M
+
 + 1), m/z 317.1789; Found m/z 317.1800;  Anal. Calcd. for C17H24N4S: C, 64.52; 
H, 7.64; N, 17.70. Found: C, 64.71; H, 7.81; N, 17.30. 
2-(4-Methylpiperazino)-4-[2-(phenylthio)ethyl]quinazoline (34, EAR-II-41(3)).  This 
compound was obtained as a yellow oil in 50% yield;   
1
H NMR for the free base (CDCl3):  δ 7.71 
(d, J = 8.4 Hz, 1H), 7.62–7.54 (m, 2H), 7.40 (d, J = 7.6 Hz, 2H), 7.30 (t, J = 7.6 Hz, 2H), 7.21 (d, J 
= 7.2 Hz, 1H), 7.14 (t, J = 6.8 Hz, 1H), 4.00 (s, 4H), 3.51–3.43 (m, 4H), 2.52 (t, J = 5.2 Hz, 4H), 
2.37 (s, 3H); 
13
C NMR for the free base (CDCl3):  δ 169.4, 158.5, 152.5, 136.4, 133.7, 129.6, 
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129.2, 126.6, 126.4, 124.5, 122.4, 118.6, 55.3, 46.4, 44.0, 33.9, 31.2.  High-resolution ms (ESI, 
positive ion mode): calcd. for C21H24N4S (M
+
 + 1), m/z 365.1791; Found m/z 365.1800.  A 
hydrobromide salt: mp 135 –137 °C.   Anal. Calcd. for C21H24N4S•2HBr•H2O: C, 46.34; H, 5.18; 
N, 10.28. Found: C, 46.14; H, 5.18; N, 9.88. 
N-Benzyl-4-[2-(benzylamino)ethyl]quinazolin-2-amine (35, EAR-I-165(2)).  Benzylamine (0.09 
mL, 0.86 mmol) was added to a mixture of 2-chloro-4-vinylquinazoline (26, 165 mg, 0.86 mmol) 
in toluene (3.0 mL).  The mixture was stirred at 60 °C overnight, after which it was cooled to room 
temperature.  The mixture was basified with sodium carbonate, extracted with Et2O (2 × 15 mL), 
dried (MgSO4), filtered and concentrated to a brown oil. The crude oil was purified by 
chromatotron with normal phase EMD 60PF254 silica gel eluting with hexanes/ethyl ether/methanol 
(4:1:0 for 100 mL, then 4:1:1 for 300 mL) to provide N-benzyl-4-[2-
(benzylamino)ethyl]quinazolin-2-amine (35, 100 mg, 32%) as an off-white solid; mp 36 – 38 °C.  
1
H NMR (CDCl3, 400 MHz):  δ 7.72 (d, J = 8.0 Hz, 1H), 7.60–7.52 (m, 2H), 7.42 (d, J = 7.4 Hz, 
2H), 7.36–7.20 (m, 8H), 7.14 (t, J = 7.4 Hz, 1H), 4.72 (d, J =5.6 Hz, 2H), 3.88 (s, 2H), 3.30 (t, J = 
6.4 Hz, 2H), 3.11 (t, J = 6.4 Hz, 2H); 
13
C NMR for the free base (CDCl3):  δ 158.5, 152.0, 139.4, 
133.6, 128.5, 127.9, 127.4, 127.2, 126.4, 124.6, 122.4, 119.1, 53.3, 46.0, 45.5, 29.7.  High-
resolution ms (ESI, positive ion mode): calcd. for C24H23N4 (M + 1)
+
, m/z 367.1939; found m/z 
367.1923.   
2-(4-Phenylpiperazin-1-yl)-4-[2-(4-phenylpiperazin-1-yl)ethyl]quinazoline (36, EAR-II-17(1)). 
N-Phenylpiperazine (0.11 mL, 0.78 mmol) was added to mixture of 2-chloro-4-vinylquinazoline 
(26, 150 mg, 0.78 mmol) in toluene (3.0 mL) under N2.  The mixture was heated to 80 °C for 1 hr, 
and then cooled to room temperature.  The mixture was basified with sodium hydroxide, extracted 
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with Et2O (2 × 15 mL), and the extract was dried (MgSO4), filtered and concentrated.  The crude 
oil was purified by chromatotron with EMD 60PF254 silica gel eluting with hexane/ethyl 
ether/methanol (4:1:0 for 100 mL, then 4:1:1 for 200 mL) to provide 2-(4-phenylpiperazin-1-yl)-
4-[2-(4-phenylpiperazino)ethyl]quinazoline as the top baseline spot (36, 38 mg, 10%) as a white 
solid;  mp 90–92 °C.  1H NMR (CDCl3, 400 MHz):  δ 7.95 (d, J = 10.8 Hz, 1H), 7.68–7.61 (m, 
2H), 7.34–7.22 (m, 5H), 7.03 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H), 6.93–6.87 (m, 2H), 4.16 
(t, J = 4.8 Hz, 4H), 3.42 (t, J = 8.0 Hz, 2H), 3.34–3.28 (m, 8H), 3.04 (t, J = 8.0 Hz, 2H), 2.80 (s, 
4H);  
13
C NMR (CDCl3, 400 MHz):  δ 152.3, 151.5, 133.6, 129.2 (2 signals), 129.1, 128.3, 128.9, 
126.5, 124.7, 122.4, 120.1, 118.5, 116.5 (2 signals), 116.2, 53.2, 53.0, 49.5, 49.0, 43.9, 29.7.  High-
resolution ms (ESI, positive ion mode): calcd. for C30H34N6 (M + 1)
+
, m/z 479.2933; found m/z 
479.2923.   
2-(4-Methylpiperazin-1-yl)quinazoline (37, EAR-II-12): 1-Methylpiperazine (0.800 mL, 7.2 
mmol) was added to a solution of 2-chloroquinazoline (25, 400 mg, 2.4 mmol) in toluene (4.0 mL).  
The mixture was heated to 90 °C for 2 hrs, after which the mixture was cooled to room 
temperature.  The mixture was basified with sodium carbonate, extracted with Et2O (2 × 20 mL), 
and the extract was dried (MgSO4), filtered and concentrated.  The crude oil was purified by 
chromatotron with normal phase EMD 60PF254 silica gel eluting with hexanes/ethyl ether/methanol 
(4:1:0 for 100, then 1:1:1 for 200 mL) to provide 2-(4-methylpiperazin-1-yl)quinazoline (37, 310 
mg, 57%) as an off-white solid; mp 80–82 °C; 1H NMR (CDCl3, 400 MHz):  δ 8.99 (s, 1H), 7.66 
(d, J = 7.8 Hz, 2H), 7.56 (d, J = 8.8 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 4.00 (t, J = 5.0 Hz, 4H), 2.52 
(t, J = 5.0 Hz, 4H), 2.36 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 161.4, 159.2, 152.3, 134.0, 
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127.3, 125.6, 122.4, 119.3, 55.1, 46.2, 44.0;  High-resolution ms (ESI, positive ion mode): calcd. 
for C13H17N4 (M
+
 + 1), m/z 229.1451; found m/z 229.1453. 
2-(4-Methylpiperazino)-4-vinylquinazoline (38, EAR-II-54).  tert-Butyllithium (3.6 mL, 6.1 
mmol) was added dropwise to a solution of tetravinyltin (0.82 mL, 4.51 mmol) in tetrahydrofuran 
(10 mL) at -78 °C.  A mixture of 2-(4-methylpiperazino)quinazoline (37, 0.93 g, 4.1 mmol) in 
tetrahydrofuran (5.0 mL) was added dropwise and the mixture was warmed to -60 °C.  The mixture 
was quenched with water:tetrahydrofuran (1:1), basified with saturated aqueous sodium hydroxide 
till pH = 9, then extracted with ether (2 × 20 mL).  The extract was dried (MgSO4), filtered and 
concentrated to provide 2-(4-methylpiperazino)-4-vinyl-3,4-dihydroquinazoline (450 mg, 45%) 
which was taken on without purification.  2-(4-Methylpiperazino)-4-vinyl-3,4-dihydroquinazoline 
(438 mg, 1.7 mmol) dissolved in benzene (11.0 mL) was added to a solution of potassium 
hydroxide (0.306 g, 5.46 mmol), and potassium ferricyanide (III) (1.3 g, 4.08 mmol) in water (2.5 
mL) under nitrogen atmosphere at room temperature.  The mixture was stirred vigorously for 5 h, 
after which benzene (20 mL) and water (20 mL) were added and the organic layer was extracted 
with Et2O (2 × 15 mL), dried (MgSO4), filtered and concentrated to provide 2-(4-
methylpiperazino)-4-vinylquinazoline (38, 0.31 g, 71 %) as a yellow solid; mp 140 – 142 °C. 1H 
NMR (CDCl3, 400 MHz):  δ 7.93 (d, J = 8.4 Hz, 1H), 7.63–7.57 (m, 2H), 7.46 (q, J = 8.4 Hz, 1H), 
7.21–7.17 (m, 1H), 6.71 (dd, J = 8.4, 2.4 Hz, 1H), 5.77 (dd, J = 5.2 , 2.0 Hz, 1H), 4.03 (t, J = 4.8 
Hz, 4H), 2.52 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H);  
13
C NMR (CDCl3, 400 MHz): δ 162.8, 158.8, 
153.8, 133.7, 130.9, 126.5, 124.6, 124.5, 122.5, 117.9, 55.4, 46.5, 44.1; High-resolution ms (ESI, 
positive ion mode): calcd. for C15H18N4 (M + 1)
+
, m/z 255.1615; Found m/z 255.1616. 
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2-Chloro-4-(3-furyl)quinazoline (39, EAR-I-131(2)): 3-Bromofuran (0.08 mL, 0.91 mmol) was 
added to THF (2.0 mL) at -78° C in a round bottom under nitrogen atmosphere.  n-Butyllithium 
(0.36 mL, 0.91 mmol, 2.5M in hexanes) was added to the solution and the mixture was warmed to 
-60 °C.  The mixture was then recooled to -78° C and 2-chloroquinazoline (25, 150 mg, 0.91 
mmol) dissolved in THF (1.0 mL) was added dropwise to form a dark brown mixture.  The 
mixture was allowed to warm to -60° C and stirred for 90 min. The mixture was quenched with 
H2O (1.0 mL) and 2,3-dichloro-5,6-dicyanoquinone (DDQ, 200 mg, 0.91 mmol) was added.  The 
mixture was allowed to warm to room temperature, extracted with hexanes/THF (1:1, 2 × 20 mL), 
and the extract was dried (MgSO4), filtered and concentrated in vacuo to a yellow solid. The solid 
was purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/ethyl acetate 
(3:1 for 300 mL) to provide 2-chloro-4-(3-furyl)quinazoline (39, 44 mg,  22%) as a yellow solid, 
mp  70 – 72 °C.  1H NMR (CDCl3, 400 MHz): δ 8.54 (d, J = 8.0 Hz, 1H), 8.22 (s, 1H), 8.06 (d, J = 
8.0 Hz, 1H), 7.97–7.94 (m, 1H), 7.74–7.66 (m, 2H), 7.11 (s, 1H).   
4-(3-furyl)-2-(4-methylpiperazino)quinazoline (40, EAR-I-132):  1-Methylpiperazine (0.06 mL, 
0.57 mmol) was added to a solution of 2-chloro-4-(3-furyl)quinazoline (39, 44 mg, 0.19 mmol) in 
toluene (1.0 mL).  The mixture was heated to 70 °C overnight, then cooled to room temperature, 
basified with potassium carbonate and extracted with EtOAc (2 × 20 mL).  The extract was dried 
(Na2SO4), filtered and concentrated in vacuo to a yellow-orange oil.  The oil was purified on a 
chromatotron with EMD 60PF254 silica gel eluting with hexanes/ethyl ether (4:1 for 100 mL, then 
1:1 for 100 mL) to provide 4-(3-furyl)-2-(4-methylpiperazino)quinazoline (40, 38 mg, 69%) as a 
yellow solid, mp = 67 – 69 °C.  1H NMR (CDCl3, 400 MHz):  δ 8.08 (m, 2H), 7.67–7.64 (m, 2H), 
7.61–7.60 (m, 1H), 7.24–7.20 (m, 1H), 7.02 (s, 1H), 4.05 (t, J = 5.0 Hz, 4H), 2.55 (t, J = 5.0 Hz, 
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4H), 2.38 (s, 3H).   
13
C NMR (CDCl3, 400 MHz): δ 161.3, 158.7, 153.5, 144.1, 143.3, 133.5, 
126.5, 126.0, 124.5, 122.4, 117.8, 111.4, 55.2, 46.3, 43.9.  MS (ESI) m/z 294 (M)
+
.  Anal Calcd. for 
C17H18N4O: C, 69.37; H, 6.16; N, 19.03. Found: C, 69.21; H, 6.16; N, 18.83. 
2-Chloro-4-(4-methylpiperazino)quinazoline (41, EAR-II-40(1)) and 2,4-bis(4-
methylpiperazino)quinazoline (42, EAR-II-40(2)):  1-Methylpiperazine (0.14 mL, 1.25 mmol) 
was added to a solution of 2,4-dichloroquinazoline (250 mg, 1.25 mmol) in toluene (4.0 mL) under 
nitrogen atmosphere.  The mixture was stirred at 70 °C, then cooled to room temperature, basified 
with sodium carbonate and extracted with Et2O (2 × 20 mL).   The extract was dried (MgSO4), 
filtered and concentrated in vacuo.  The crude residue was purified on a chromatotron with EMD 
60PF254 silica gel eluting with dichloromethane/methanol (100:0 for 100 mL, then 9:1 for 250 mL) 
to provide 2-chloro-4-(4-methylpiperazino)quinazoline (41, 103 mg, 31%) as a colorless oil.  
Also isolated was 2,4-bis(4-methylpiperazino)quinazoline (42, 60 mg, 18%) as a colorless oil. 
2-Chloro-4-(4-methylpiperazino)quinazoline (41, EAR-II-40(1)).  
1
H NMR (CDCl3):  δ 7.85 (d, 
J = 8.4 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 3.90 (t, 
J = 4.6 Hz, 4H), 2.60 (t, J = 4.6 Hz, 4H), 2.37 (s, 3H).  
13
C NMR (CDCl3, 400 MHz):  δ 165.4, 
156.5, 153.5, 133.4, 128.1, 125.4, 125.3, 114.8, 54.9, 49.7, 46.2.  
2,4-Bis(4-methylpiperazino)quinazoline (42, EAR-II-40(2)). 
1
H NMR (CDCl3):  δ 7.67 (d, J = 
8.4 Hz, 1H), 7.51 (m, 2H), 7.07–7.03 (m, 1H), 3.93 (bs, 4H), 3.70 (t, J = 4.6 Hz, 4H), 2.61 (t, J = 
4.6 Hz, 4H), 2.51 (t, J = 4.6 Hz, 4H), 2.37 (d, J = 7.2 Hz, 6H) ; 
13
C NMR (CDCl3, 400 MHz):  δ 
165.8, 158.4, 154.6, 132.6, 126.4, 125.3, 120.8, 112.2, 55.3, 55.1, 49.9, 46.4, 46.4, 44.1;  High-
resolution ms (ESI, positive ion mode): calcd. for C18H27N6 (M + 1)
+
, m/z 327.2282; Found m/z 
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327.2297.  A hydrobromide salt, mp 108–112 °C dec.  Anal Calcd. for C18H26N6•2HBr: C, 44.28; 
H, 5.78; N, 17.21. Found: C, 44.60; H, 5.73; N, 17.42. 
4-(4-Methylpiperazino)-2-(4-phenylpiperazino)quinazoline (43, EAR-II-43(4)). N-
Phenylpiperazine (0.17 mL, 1.14 mmol) was added to a solution of 2-chloro-4-(4-
methylpiperazino)quinazoline (100 mg, 0.38 mmol) in toluene (3.0 mL) under nitrogen 
atmosphere.  The mixture was stirred at 80 °C overnight, then cooled to room temperature, basified 
with sodium carbonate and extracted with Et2O (2 × 30 mL).  The extract was dried (MgSO4), 
filtered and concentrated in vacuo.  The crude residue was purified on a chromatotron with normal 
phase EMD 60PF254 silica gel eluting with dichloromethane/methanol (100:0 for 100 mL, then 9:1 
for 250 mL, and finally 7:1 for 100 mL) to provide 4-(4-methylpiperazino)-2-(4-
phenylpiperazino)quinazoline (43, 40 mg, 27%) as an off-white solid, mp 48 – 50 °C.  1H NMR 
(CDCl3):  δ 7.69 (d, J = 8.0 Hz, 1H), 7.54–7.52 (m, 2H), 7.31–7.25 (m, 2H), 7.09–7.05 (m, 1H), 
6.99 (d, J = 8.0 Hz, 2H), 6.88 (t, J = 7.2 Hz, 1H), 4.06 (t, J = 5.2 Hz, 4H), 3.72 (t, J = 4.6 Hz, 4H), 
3.27 (t, J = 5.2 Hz, 4H), 2.65 (t, J = 4.6 Hz, 4H), 2.38 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  
δ165.9, 158.5, 154.5, 151.7, 132.6, 129.4, 126.4, 125.3, 120.9, 120.2, 116.4, 112.3, 55.1, 49.9, 
49.8, 46.4, 44.2;  High-resolution ms (ESI, positive ion mode): calcd. for C23H29N6 (M + 1)
+
, m/z 
389.2457; Found m/z 389.2454. 
5.5 Synthesis of Benzenes 
2,6-Dibromo-4-butylbenzenamine (45, EAR-II-106(2)).  N-Bromosuccinimide (14.0 g, 79.1 
mmol) dissolved in N,N,-dimethylformamide (40 mL) was added to a solution of 4-butylaniline 
(44, 5.0 mL, 31.6 mmol) in N,N,-dimethylformamide (40 mL) at 0 °C dropwise.  The mixture was 
stirred at 0 °C for 3 h, and concentrated to dryness in vacuo.  The crude residue was purified by 
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through a plug of silica gel (2.0 g), eluting with hexanes (4.0 L) and concentrated to provide 2,6-
dibromo-4-butylbenzenamine as a red solid in 49% yield (4.73 g).  
1
H NMR (CDCl3, 400 MHz): 
δ 7.19 (s, 2H), 4.39 (bs, 2H), 2.45 (t, J = 7.6 Hz, 2H), 1.55–1.50 (m, 2H), 1.34–1.25 (m, 2H), 0.91 
(t, J = 7.6 Hz, 3H);  
13
C NMR (CDCl3, 400 MHz):  δ139.8, 134.7, 131.7, 108.9, 34.3, 33.7, 22.3, 
14.1;  High-resolution ms (ESI, positive ion mode): calcd. for C10H13Br2N (M + 1)
+
, m/z 305.9493; 
Found m/z 305.9492.   
1,3-Dibromo-5-butylbenzene (46, EAR-II-110(3)).  2,6-Dibromo-4-butylbenzeneamine (45, 4.7 
g, 15.3 mmol), ethanol (94 mL) and sulfuric acid (5.8 mL) were combined in a round bottom flask 
and heated to 75 °C.  Sodium nitrite (3.1 g, 45.9 mmol) was added in small portions and the 
mixture was stirred at 75 °C for 2 h, then cooled in an ice bath, and treated with ice-H2O (40 mL).  
The mixture was extracted with CH2Cl2 (2 × 150 mL), dried (MgSO4), filtered and concentrated in 
vacuo.  The crude residue was purified on a chromatotron with EMD 60PF254 silica gel eluting 
with hexanes (100% for 200 mL) to provide 1,3-dibromo-5-butylbenzene (46, 2.3 g) as a clear 
yellow oil in 50 % yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.47 (s, 1H), 7.25 (s, 2H), 2.54 (t, J = 7.4 
Hz, 2H), 1.60–1.52 (m, 2H), 1.38–1.29 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 400 
MHz):  δ147.0, 133.2, 131.4 (2 signals), 130.5, 122.8, 35.2, 33.3, 22.4, 14.0. 
1-(3-Bromophenyl)-4-methylpiperazine (50, EAR-II-84).  (Method A) 1,3-Dibromobenzene 
(47, 5.0 g, 21.1 mmol), N-methylpiperazine (0.77 mL, 6.96 mmol), and toluene (20 mL) were 
stirred in a round bottom flask under nitrogen atmosphere for 5 min.  2,2'-Bis(diphenylphosphino)-
1,1'-binaphthyl (BINAP, 0.13 g, 0.21 mmol) and tris(dibenzylideneacetone)dipalladium(0) 
(Pd2dba3, 0.05 g, 0.06 mmol) were added quickly and the flask was refilled with nitrogen, after 
which 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 2.6 mL, 17.5 mmol) was added via syringe.  The 
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mixture was warmed to 60 °C before treatment with sodium tert-butoxide (0.01 g, 0.05 mmol) in 
one portion.  The mixture was then heated to 110 °C overnight, then cooled and partitioned 
between EtOAc (40 mL) and water (40 mL).  The aqueous layer was extracted with EtOAc (40 
mL).  The organic layers were combined and washed with 1.6 M HCl (2 × 25 mL).  The aqueous 
acidic layer containing product was basified with a 1M NaOH solution (50 mL), and then solid 
sodium bicarbonate was added to pH = 8.5, and the mixture was extracted with EtOAc (2 × 40 
mL).  The organic layers were washed with brine (25 mL), dried over magnesium sulfate, filtered 
and concentrated in vacuo to provide 50.  This compound was obtained as a brown oil in 27% 
yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.09 (t, J = 8.0 Hz, 1H), 7.03 (s, 1H), 6.94 (d, J = 8.0 Hz, 
1H), 6.82 (dd, J = 8.0, 2.0 Hz, 1H), 3.20 (t, J = 4.8 Hz, 4H), 2.55 (4.8 Hz, 4H), 2.34 (s, 3H); 
13
C 
NMR (CDCl3, 400 MHz):  δ 152.6, 130.5, 123.4, 122.3, 118.8, 114.5, 55.1, 48.8, 46.3;  High-
resolution ms (ESI, positive ion mode): calcd. for C11H15BrN2 (M + 1)
+
, m/z 255.0497; Found m/z 
255.0493.   
Compounds 49 & 51. (Method B).  Compounds 46 or 48 (1.0 g, 3.4 mmol), N-methylpiperazine 
(0.37 mL, 3.4 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.15 g, 0.25 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (0.15 g, 0.17 mmol) and sodium tert-butoxide (0.39 g, 
4.08 mmol) in toluene (6.0 mL) were combined in a sealed tube and the mixture was heated to 80 
°C overnight.  The mixture was partitioned between EtOAc (10 mL) and water (10 mL).  The 
aqueous layer was extracted and washed with EtOAc (10 mL), and the organic layers were 
combined and washed with a 1.6 M HCl solution (2 × 5 mL).  The aqueous acidic layer containing 
product was then basified with a 1M NaOH solution (10 mL), and solid sodium bicarbonate was 
added to pH = 8.5 before extraction with EtOAc (2 × 15 mL).  The organic layers were washed 
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with brine (10 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to provide 49 
and 51. 
1-(3-Bromophenyl)-4-methylpiperazine (49, EAR-II-122).  This compound was obtained as a 
clear yellow oil in 28% yield.  
1
H NMR (CDCl3, 400 MHz): δ 6.85 (t, J = 2.0 Hz, 1H), 6.80 (s, 
1H), 6.64 (s, 1H), 3.19 (t, J = 5.2 Hz, 4H), 2.56–2.49 (m, 6H), 2.34 (s, 3H), 1.58–1.54 (m, 2H), 
1.37–1.31 (m, 2H), 0.91 (t, J = 7.6 Hz, 3H);  13C NMR (CDCl3, 400 MHz):  δ 152.3, 145.5, 122.9, 
122.4, 116.0, 114.7, 55.0, 48.7, 46.1, 35.8, 33.4, 22.3, 13.9;  High-resolution ms (ESI, positive ion 
mode): calcd. for C15H13BrN2 (M + 1)
+
, m/z 311.1123; Found m/z 311.1133.  
1-(3-Bromo-5-methylphenyl)-4-methylpiperazine (51, EAR-II-85).  This compound was 
obtained as a brown oil in 54% yield.  
1
H NMR (CDCl3, 400 MHz): δ 6.84 (s, 1H), 6.80 (s, 1H), 
6.63 (s, 1H), 3.19 (t, J = 4.8 Hz, 4H), 2.54 (t, J = 4.8 Hz, 4H), 2.34 (s, 3H), 2.27 (s, 3H);  
13
C NMR 
(CDCl3, 400 MHz):  δ 152.5, 140.6, 131.1, 123.2, 116.1, 115.4, 55.2, 48.9, 46.3, 21.7;  High-
resolution ms (ESI, positive ion mode): calcd. for C12H17BrN2 (M + 1)
+
, m/z 269.0653; Found m/z 
269.0653.   
General Procedure for synthesis of compounds 52 – 58. (Method A).  A mixture of a boronic 
acid (3-furanboronic acid, 3-thiopheneboronic acid, 2-furanboronic acid, and 2-thiopheneboronic 
acid) (0.112 g, 0.88 mmol), 50 or 51 (0.150 g, 0.59 mmol), 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.02 g, 0.05 mmol), and potassium phosphate 
(0.221 g, 1.04 mmol) in 1,4-dioxane (6.0 mL) was degassed with nitrogen and the mixture was 
stirred at 100 °C over 7 days.   The mixture was cooled to room temperature, filtered through 
Celite™, washed with Et2O (20 mL), and concentrated to provide crude residues 52 – 58.  These 
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products were purified by chromatography eluting with hexanes/diethyl ether (80:20) to give 52 – 
58. 
1-[3-(3-Furyl)phenyl]-4-methylpiperazine (52, EAR-II-86(2)). This compound was obtained as 
a yellow oil in 28% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.70 (s, 1H), 7.46 (s, 1H), 7.26 (t, J = 
5.6 Hz, 1H), 7.03 (s, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.85 (dd, J = 8.4, 1.6 Hz, 1H), 6.68 (s, 1H);   
13
C NMR (CDCl3, 400 MHz):  δ 151.9, 143.6, 138.7, 133.5, 129.7, 127.1, 117.8, 115.0, 113.9, 
109.2, 55.3, 49.3, 46.3;  High-resolution ms (ESI, positive ion mode): calcd. for C15H18N2O (M + 
1)
+
, m/z 243.1497; Found m/z 243.1492.   A hydrobromide salt: a white solid, mp 215 – 217 °C.  
Anal Calcd. for C15H18N2O•2HBr: C, 44.58; H, 4.99; N, 6.93. Found: C, 44.31; H, 4.99; N, 6.52. 
1-Methyl-4-[3-(3-thienyl)phenyl]piperazine (53, EAR-II-81(2)). This compound was obtained 
as a clear colorless oil in 22% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.42 (t, J = 2.0 Hz, 1H), 7.36 
(d, J = 2.0 Hz, 2H), 7.29 (t, J = 8.0 Hz, 1H), 7.14 (s, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.87 (dd, J = 
8.0, 2.0 Hz, 1H), 3.27 (t, J = 4.8 Hz, 4H), 2.62 (t, J = 4.8 Hz, 4H), 2.38 (s, 3H);  
13
C NMR (CDCl3, 
400 MHz):  δ 151.8, 143.1, 137.0, 129.7, 126.7, 126.2, 120.5, 118.5, 115.2, 114.6, 55.3, 49.3, 46.3;  
High-resolution ms (ESI, positive ion mode): calcd. for C15H18N2S (M + 1)
+
, m/z 259.1269; Found 
m/z 259.1269.  A hydrobromide salt: a white solid, mp 200 – 205 °C dec.  Anal Calcd. for 
C15H18N2S•3HBr: C, 35.95; H, 4.22; N, 5.66. Found: C, 35.97; H, 4.19; N, 5.66. 
1-Methyl-4-[3-(2-thienyl)phenyl]piperazine (54, EAR-II-87(3)). This compound was obtained 
as a clear colorless oil in 21% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.29–7.24 (m, 3H), 7.15 (s, 
1H), 7.10 (d, J = 8.4 Hz, 1H), 7.06 (t, J = 4.4 Hz, 1H), 6.86 (dd, J = 8.4, 2.0 Hz, 1H), 3.26 (t, J = 
4.8 Hz, 4H), 2.59 (t, J = 4.8 Hz, 4H), 2.36 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 151.7, 144.9, 
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135.2, 129.6, 127.8, 124.6, 123.0, 117.7, 115.2, 113.8, 55.1, 49.0, 46.1;  High-resolution ms (ESI, 
positive ion mode): calcd. for C15H18N2S (M + 1)
+
, m/z 259.1269; Found m/z 259.1279.   A 
hydrobromide salt: a white solid, mp >250 C.  Anal Calcd. for C15H18N2S•2HBr: C, 42.87; H, 4.80; 
N, 6.67. Found: C, 42.45; H, 4.78; N, 6.65. 
1-[3-(2-Furyl)phenyl]-4-methylpiperazine (55, EAR-II-105(2)).  This compound was obtained 
as a clear colorless oil in 24% yield.  
1
H NMR (CDCl3, 400 MHz): δ  7.44 (s, 1H), 7.28–7.25 (m, 
2H), 7.16 (d, J = 7.6 Hz. 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.62 (d, J = 3.2 Hz, 1H), 6.45 (s, 1H), 3.27 
(t, J = 4.6 Hz, 4H), 2.60 (t, J = 4.6 Hz, 4H), 2.36 (s, 3H);  
13
C NMR (CDCl3, 400 MHz):  δ 154.5, 
151.7, 142.0, 131.8, 129.6, 115.7, 115.4, 111.7, 111.5, 105.1, 55.3, 49.2, 46.3;  High-resolution ms 
(ESI, positive ion mode): calcd. for C15H18N2O (M + 1)
+
, m/z 243.1497; Found m/z 243.1487.  A 
hydrobromide salt: a white solid, mp 240 – 242 °C.  Anal Calcd. for C15H18N2O•2HBr, 0.5 H2O: C, 
43.61; H, 5.12; N, 6.78. Found: C, 43.24; H, 5.12; N, 7.15.  
1-[3-(3-Furyl)-5-methylphenyl]-4-methylpiperazine (56, EAR-II-88(2)).  This compound was 
obtained as a clear colorless oil in 23% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.68 (s, 1H), 7.44 (s, 
1H), 6.85 (s, 1H), 6.82 (s, 1H), 6.67 (s, 2H), 3.23 (t, J = 4.8 Hz, 4H), 2.59 (t, J = 4.8 Hz, 4H), 2.34 
(d, J = 8.8 Hz, 6H);  
13
C NMR (CDCl3, 400 MHz):  δ 151.7, 143.4, 139.2, 138.5, 133.1, 126.9, 
118.6, 115.7, 111.1, 109.1, 55.1, 49.2, 46.1, 21.7;  High-resolution ms (ESI, positive ion mode): 
calcd. for C16H20N2O (M + 1)
+
, m/z 257.1654; Found m/z 257.1657.   A hydrobromide salt: a white 
solid, mp 230 – 232 °C.  Anal Calcd. for C16H20N2O•2HBr: C, 45.96; H, 5.30; N, 6.70. Found: C, 
46.30; H, 5.28; N, 6.34. 
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1-Methyl-4-[3-methyl-5-(3-thienyl)phenyl]piperazine (57, EAR-II-98(2)). This compound was 
obtained as a clear colorless oil in 20% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.40 (s, 1H), 7.35 (s, 
2H), 6.95 (s, 1H), 6.92 (s, 1H), 6.70 (s, 1H), 3.25 (t, J = 4.8 Hz, 4H), 2.61 (t, J = 4.8 Hz, 4H), 2.35 
(d, J = 5.2 Hz, 6H);  
13
C NMR (CDCl3, 400 MHz):  δ 151.9, 143.1, 139.3, 136.9, 126.8, 126.0, 
120.3, 119.4, 116.0, 111.9, 55.3, 49.3, 46.2, 22.0;  High-resolution ms (ESI, positive ion mode): 
calcd. for C16H20N2S (M + 1)
+
, m/z 273.1425; Found m/z 273.1432.   A hydrobromide salt: a white 
solid, mp 245 – 247 °C .  Anal Calcd. for C16H20N2S•1.5HBr,2H2O: C, 44.89; H, 4.85; N, 6.03. 
Found: C, 44.71; H, 5.23; N, 6.42. 
1-Methyl-4-[3-methyl-5-(2-thienyl)phenyl]piperazine (58, EAR-II-103 (2)). This compound 
was obtained as a clear colorless oil in 25% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.26 (t, J = 8.0 
Hz, 2H), 7.05 (t, J = 3.6 Hz, 1H), 6.97 (d, J = 9.6 Hz, 2H), 6.69 (1H), 3.26 (t, J = 4.8 Hz, 4H), 2.62 
(t, J = 4.8 Hz, 4H), 2.35 (d, J = 12 Hz, 6H); 
13
C NMR (CDCl3, 400 MHz):  δ 151.7, 145.0, 139.3, 
135.1, 127.8, 124.4, 123.0, 118.7, 116.2, 111.1, 55.1, 49.1, 46.1, 21.7;  High-resolution ms (ESI, 
positive ion mode): calcd. for C16H20N2S (M + 1)
+
, m/z 273.1425; Found m/z 273.1434.  A 
hydrobromide salt: a white solid, mp >250 °C.  Anal Calcd. for C16H20N2S•2HBr, 0.5 H2O: C, 
43.36; H, 5.23; N, 6.23. Found: C, 43.47; H, 5.15; N, 6.71. 
 
1-(3-Butyl-5-(3-thienyl)phenyl)-4-methylpiperazine (61, EAR-II-126 (2)). (Method B).   A 
mixture of 3-thienylboronic acid (0.09 g, 0.77 mmol), 1-(3-bromophenyl)-4-methylpiperazine 
(0.17 g, 0.51 mmol), tetrakis(triphenylphosphine)palladium (0.04 g, 0.04 mmol), potassium 
carbonate (0.21 g, 1.53 mmol) in 1,4-dioxane (5.0 mL) and water (0.3 mL) was degassed with N2 
gas and the reaction was stirred at 100 °C overnight.   The mixture was cooled to room temperature 
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and filtered through Celite™, washed with Et2O (20 mL), and evaporated to provide crude residue 
61.  The crude residue was purified by chromatography eluting with hexanes/diethyl ether (80:20) 
to give 61.  This compound was obtained as a clear colorless oil in 23% yield.  
1
H NMR (CDCl3, 
400 MHz): δ 7.40 (t, J = 2.4 Hz, 1H), 7.35 (s, 2H), 6.96 (s, 1H), 6.92 (s, 1H), 6.71 (s, 1H), 3.26 (t, 
J = 4.8 Hz, 4H), 2.62–2.58 (m, 6H), 2.36 (s, 3H), 1.66–1.58 (m, 2H), 1.43–1.35 (m, 2H), 0.93 (t, J 
= 7.6 Hz, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 151.9, 144.5, 143.3, 136.8, 126.9, 126.0, 120.3, 
118.9, 115.6, 112.1, 55.4, 49.5, 46.3, 36.3, 33.9, 22.7, 14.2;  High-resolution ms (ESI, positive ion 
mode): calcd. for C19H26N2S (M + 1)
+
, m/z 315.1895; Found m/z 315.1910.  A hydrobromide salt: 
a white solid, mp 215 – 217 °C.  Anal Calcd. for C19H26N2S•2HBr: C, 47.91; H, 5.93; N, 5.88. 
Found: C, 47.50; H, 6.19; N, 6.20.    
General Procedure for Substitution of bromide with boronic acids (59 – 60 & 62 – 65). 
(Method C). Compounds 59 – 60 & 62 – 65 were synthesized as previously described with slight 
modifications.
47
  A mixture of a selected boronic acid (0.20 g, 1.8 mmol), 49 or 50 (0.32 g, 1.2 
mmol), tetrakis(triphenylphosphine)palladium (0.10 g, 0.09 mmol), and potassium carbonate 
(0.497 g, 3.6 mmol) in dimethylformamide (5.0 mL) and water (0.5 mL) were combined in a 
sealed tube, degassed with N2 gas and allowed to stir at 90 °C overnight.   The mixture was cooled 
to room temperature and filtered through Celite™, washed with ethyl acetate (20 mL), and 
evaporated to provide crude residues 59 – 60 & 62 – 65.  The crude residues were purified by 
chromatography eluting with hexanes/diethyl ether (80:20) to give 59 – 60 & 62 – 65. 
1-(3-Furan-2-yl)-5-methylphenyl)-4-methylpiperazine  (59, EAR-II-135(2)). This compound 
was obtained as a clear colorless oil in 12% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.46 (s, 1H), 
7.09 (s, 1H), 7.03 (s, 1H), 6.69 (s, 1H), 6.63 (d, J = 3.6 Hz, 1H), 6.47 (dd, J = 2.0, 3.2 Hz, 1H), 
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3.31 (t, J = 5.0 Hz, 4H), 2.67 (t, J = 5.0 Hz, 4H), 2.42 (s, 3H), 2.36 (s, 3H); 
13
C NMR (CDCl3, 400 
MHz):  δ154.4, 151.4, 141.7, 139.1, 131.5, 116.6, 116.2, 111.5, 108.9, 104.8, 54.9, 48.9, 45.8, 
21.8;  High-resolution ms (ESI, positive ion mode): calcd. for C16H20N2O (M + 1)
+
, m/z 257.1654; 
Found m/z 257.1651.  A hydrobromide salt: a white solid, mp 245 – 249 °C.  Anal Calcd. for 
C16H20N2O•2HBr: C, 45.96; H, 5.30; N, 6.70. Found: C, 45.64; H, 5.26; N, 6.81.    
1-[3-Butyl-5-(3-furyl)phenyl]-4-methylpiperazine (60, EAR-II-129). This compound was 
obtained as a clear colorless oil in 70% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.69 (s, 1H), 7.43 (t, 
J = 1.6 Hz, 1H), 6.85 (s, 1H), 6.82 (s, 1H), 6.67 (d, J = 6.8 Hz, 2H), 3.23 (t, J = 5.2 Hz, 4H), 2.58–
2.56 (m, 6H), 2.34 (s, 3H), 1.65–1.57 (m, 2H), 1.40–1.34 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H); 13C 
NMR (CDCl3, 400 MHz):  δ 151.8, 144.4, 143.4, 138.5, 133.1, 127.1, 118.1, 115.4, 111.3, 109.2, 
55.3, 49.4, 46.2, 36.2, 33.8, 22.6, 14.1;  High-resolution ms (ESI, positive ion mode): calcd. for 
C19H26N2O (M + 1)
+
, m/z 299.2123; Found m/z 299.2136. A hydrobromide salt: a white solid, mp 
215 – 219 °C.  Anal Calcd. for C19H26N2O•2HBr, 0.5 H2O: C, 48.63; H, 6.23; N, 5.97. Found: C, 
48.55; H, 6.14; N, 6.20.    
1-[3-Butyl-5-(2-thienyl)phenyl]-4-methylpiperazine  (62, EAR-II-136(2)). This compound was 
obtained as a clear colorless oil in 24% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.27–7.23 (m, 2H), 
7.06–7.04 (m, 1H), 6.97 (t, J = 2.0 Hz, 1H), 6.94 (s, 1H), 6.70 (s, 1H), 3.25 (t, J = 5.2 Hz, 4H), 
2.60–2.57 (m, 6H), 2.6 (s, 3H), 1.64–1.58 (m, 2H), 1.40–1.35 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H);  
13
C NMR (CDCl3, 400 MHz):  δ 151.9, 145.4, 144.6, 135.2, 127.9, 124.6, 123.1, 118.3, 115.9, 
111.5, 55.3, 49.4, 46.3, 36.2, 33.8, 22.7, 14.2;  High-resolution ms (ESI, positive ion mode): calcd. 
for C19H26N2O (M + 1)
+
, m/z 315.1895; Found m/z 315.1885. A hydrobromide salt: a white solid, 
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mp 234 – 236 °C.  Anal Calcd. for C19H26N2S•1.5HBr: C, 52.36; H, 6.36; N, 6.43. Found: C, 
52.01; H, 6.40; N, 6.50.      
 
1-[3-Butyl-5-(2-furyl)phenyl]-4-methylpiperazine  (63, EAR-II-134). This compound was 
obtained as a clear colorless oil in 76% yield.  
1
H NMR (CDCl3, 400 MHz): δ7.44 (s, 1H), 7.07 (s, 
1H), 7.01 (s, 1H), 6.68 (s, 1H), 6.61 (d, J = 3.2 Hz, 1H), 6.45 (q, J = 3.2 Hz, 1H), 3.26 (t, J = 4.8 
Hz, 4H), 2.59 (t, J = 5.6 Hz, 6H), 2.36 (s, 3H), 1.65–1.58 (m, 2H), 1.40–1.34 (m, 2H), 0.93 (t, J = 
7.2 Hz, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 154.7, 151.7, 144.4, 141.9, 131.7, 116.1, 116.0, 
111.7, 109.2, 105.0, 55.3, 49.3, 46.2, 36.3, 33.8, 22.6, 14.2;  High-resolution ms (ESI, positive ion 
mode): calcd. for C19H26N2O (M + 1)
+
, m/z 299.2123; Found m/z 299.2124. A hydrobromide salt: a 
white solid, mp 180 – 182 °C.  Anal Calcd. for C19H26N2O•HBr: C, 60.16; H, 7.17; N, 7.38. Found: 
C, 60.37; H, 7.15; N, 7.54.    
1-Methyl-4-(5-methylbiphenyl-3-yl)piperazine (64, EAR-II-173). This compound was obtained 
as a white solid in 25% yield, mp 30 – 32 °C.   1H NMR (CDCl3, 400 MHz): δ 7.57–7.54 (m, 2H), 
7.42–7.38 (m, 2H), 7.34–7.31 (m, 1H), 6.94 (s, 1H), 6.90 (s, 1H), 6.75 (s, 1H), 3.26 (t, J = 4.8 Hz, 
4H), 2.59 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H), 2.35 (s, 3H);  
13
C NMR (CDCl3, 400 MHz):  δ 151.9, 
142.4, 142.1, 139.3, 128.8, 127.4, 127.3, 120.0, 116.0, 112.6, 55.4, 49.4, 46.3, 22.0;  High-
resolution ms (ESI, positive ion mode): calcd. for C18H22N2 (M + 1)
+
, m/z 267.1861; Found m/z 
267.1870. Anal Calcd. for C18H22N2: C, 81.16; H,8.32 ; N, 10.52. Found: C, 81.15; H, 8.52; N, 
10.30.     
 1-Methyl-4-[3-methyl-5-(5-methyl-2-thienyl)phenyl]piperazine (65, EAR-II-175(6)). This 
compound was obtained brown oil in 15% yield.   
1
H NMR (CDCl3, 400 MHz): δ 7.06 (d, J = 3.2 
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Hz, 1H), 6.91 (s, 1H), 6.88 (s, 1H), 6.69 (dd, J = 3.6, 1.2 Hz, 1H), 6.65 (s, 1H), 3.23 (t, J = 5.2 Hz, 
4H), 2.58 (t, J = 4.8 Hz, 4H), 2.49 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H). A hydrobromide salt: a white 
solid, mp 238 – 240 °C.   Anal Calcd. for C17H22N2S•1.5HBr,H2O: C, 47.95; H, 6.04; N, 6.58. 
Found: C, 47.84; H, 5.89; N, 6.65.    
1-(4-Bromophenyl)-4-methylpiperazine (67, EAR-II-148). 1,4-Dibromobenzene (1.0 g, 4.2 
mmol), N-methylpiperazine (0.46 mL, 4.2 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
(BINAP, 0.20 g, 0.31 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.19 g, 0.21 mmol) and 
sodium tert-butoxide (0.48 g, 5.04 mmol) in toluene (6.0 mL) were combined in a sealed tube and 
heated to 80 °C overnight.  The mixture was partitioned between EtOAc (10 mL) and water (10 
mL).  The aqueous layer was extracted and washed with EtOAc (10 mL), and the organic layers 
were combined and washed with 1.6 M HCl (2 × 5 mL).  The aqueous acidic layer containing 
product was then basified with an aqueous 1M NaOH solution to pH = 8.5 before an extraction 
with EtOAc (2 × 15 mL).  The organic layers were washed with brine (10 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo to provide 1-(4-bromophenyl)-4-
methylpiperazine (499 mg, 47%) as a brown oil. 
1
H NMR (CDCl3, 400 MHz): δ 7.33 (d, J = 10.4 
Hz, 2H), 6.79 (d, J = 10.4 Hz, 2H), 3.17 (t, J = 4.8 Hz, 4H), 2.56 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 150.2, 131.8, 117.6, 111.8, 54.9, 48.9, 46.1. 
General Procedure for Synthesis of 1,4-Substituted Benzenes 68 – 69.  A mixture of a boronic 
acid (3-thiopheneboronic acid or 2-furanboronic acid) (0.14 g, 1.17 mmol), 1-(4-bromophenyl)-4-
methylpiperazine (65, 0.20 g, 0.78 mmol), tetrakis(triphenylphosphine)palladium (0.07 g, 0.06 
mmol), and potassium carbonate (0.32 g, 2.34 mmol) in dimethylformamide (5.0 mL) and water 
(0.4 mL) were combined in a sealed tube, degassed with N2 gas and allowed to stir at 90 °C 
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overnight.   The mixture was cooled to room temperature and filtered through Celite™, washed 
with ethyl acetate (20 mL), and evaporated to provide crude residues.  The crude residues were 
purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/diethyl ether (80:20) 
to provide pure 68 and 69. 
1-Methyl-4-(4-(3-thienyl)phenyl)piperazine (68, EAR-II-140(4)).  This compound was obtained 
as a white solid in 16% yield, mp = 207 – 208 °C.  1H NMR (CDCl3, 400 MHz): δ 7.50 (d, J = 8.8 
Hz, 2H), 7.34–7.32 (m, 3H), 6.95 (d, J = 8.8 Hz, 2H), 3.204 (t, J = 4.8 Hz, 4H), 2.59 (t, J = 4.8 Hz, 
4H), 2.36 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 150.5, 142.4, 127.6, 127.4, 126.3, 126.1, 118.6, 
116.2, 55.3, 49.1, 46.3;  High-resolution ms (ESI, positive ion mode): calcd. for C15H18N2S (M + 
1)
+
, m/z 259.1269; Found m/z 259.1274. Anal Calcd. for C15H18N2: C, 69.73; H, 7.02; N, 10.84. 
Found: C, 69.29; H, 7.13; N, 10.74.     
1-(4-(2-Furyl)phenyl)-4-methylpiperazine (69, EAR-II-149).  This compound was obtained as a 
white solid in 29% yield, mp 151 – 154 °C.  1H NMR (CDCl3, 400 MHz): δ 7.60 (d, J = 13.2 Hz, 
2H), 7.43 (s, 1H), 6.96 (d, J = 13.2 Hz, 2H), 6.51 (d, J = 4.8 Hz, 1H), 6.50–6.44 (m, 1H), 3.27 (t, J 
= 4.8 Hz, 4H), 2.61 (t, J = 4.8 Hz, 4H), 2.38 (s, 3H);
 13
C NMR (CDCl3, 400 MHz):  δ 155.2, 150.3, 
141.1, 124.8, 122.7, 115.8, 111.5, 102.9, 54.9, 48.6, 46.0; Anal Calcd. for C15H18N2O: C, 74.35; H, 
7.49; N, 11.56. Found: C, 74.08; H, 7.47; N, 11.81.    
1-(3,5-Dibromophenyl)-4-methylpiperazine (71 , EAR-II-169).  1,3,5-Tribromobenzene (1.0 g, 
3.1 mmol), N-methylpiperazine (0.34 mL, 3.1 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
(BINAP, 0.14 g, 0.23 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.14 g, 0.15 mmol) and 
sodium tert-butoxide (0.36 g, 3.72 mmol) in toluene (12.0 mL) were combined in a sealed tube and 
heated to 80 °C overnight.  The mixture was partitioned between EtOAc (10 mL) and water (10 
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mL).  The aqueous layer was extracted and washed with EtOAc (10 mL), and the organic layers 
were combined and washed with 1.6 M HCl (2 × 5 mL).  The aqueous acidic layer containing 
product was then basified with an aqueous solution of 1M NaOH to pH = 8.5 before an extraction 
with EtOAc (2 × 15 mL).  The organic layers were washed with brine (10 mL), dried over 
magnesium sulfate, filtered and concentrated in vacuo to provide 1-(3,5-dibromophenyl)-4-
methylpiperazine (71, 557 mg, 56%) as a brown oil. 
1
H NMR (CDCl3, 400 MHz): δ 7.08 (t, J = 1.6 
Hz, 1H), 6.93 (d, J = 1.6 Hz, 2H), 3.20 (t, J = 5.0 Hz, 4H), 2.54 (t, J = 5.0 Hz, 2.35 (s, 3H). 
1-(3,5-Di(3-furyl)phenyl)4-methylpiperazine (72, EAR-II-171(2)).  A mixture of  3-
furanboronic acid (0.60 g, 4.99 mmol), 1-(3,5-dibromophenyl)-4-methylpiperazine (69, 0.56 g, 
1.66 mmol), tetrakis(triphenylphosphine)palladium (0.19 g, 0.16 mmol), and potassium carbonate 
(0.69 g, 4.99 mmol) in dimethylformamide (12.0 mL) and water (1.0 mL) were combined in a 
sealed tube, degassed with nitrogen and allowed to stir at 90 °C overnight.   The mixture was 
cooled to room temperature and filtered through Celite™, washed with ethyl acetate (20 mL), and 
evaporated to provide crude residues.  The crude residues were purified on a chromatotron with 
EMD 60PF254 silica gel eluting with hexanes/diethyl ether (80:20 over 100 mL, the 80:15(with 5% 
methanol) to provide 1-(3,5-di(3-furyl)phenyl)4-methylpiperazine (72, 23.0 mg, 4%) as a white 
solid, mp = 57 – 59 ˚C.  1H NMR (CDCl3, 400 MHz): δ 7.71 (s, 2H), 7.46 (t, J = 2.0 Hz, 2H), 7.08 
(s, 1H), 6.93 (d, J = 1.2 Hz, 2H), 6.68 (t, J = 1.6 Hz, 2H), 3.27 (t, J = 4.8 Hz, 4H), 2.59 (t, J = 4.8 
Hz, 4H), 2.35 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 152.3, 143.7, 138.8, 133.9, 126.9, 115.8, 
112.8, 109.2, 55.2, 49.3, 46.3;  High-resolution ms (ESI, positive ion mode): calcd. for C19H20N2O2 
(M + 1)
+
, m/z 309.1603; Found m/z 309.1611.  Anal Calcd. for C19H20N2O2 : C, 74.00; H, 6.54; N, 
9.08. Found: C, 73.90; H, 6.85; N, 8.80.      
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1-Benzyl-4-(3-bromo-5-methylphenyl)piperazine (73, EAR-II-177(2)).  3,5-Dibromotoluene 
(5.0 g, 20.0 mmol), benzylpiperazine (1.7 mL, 10.0 mmol), 2,2'-Bis(diphenylphosphino)-1,1'-
binaphthyl (BINAP, 0.46 g, 0.75 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.45 g, 0.50 
mmol) and sodium tert-butoxide (1.72 g, 18.0 mmol) in toluene (20.0 mL) were combined in a 
sealed tube and heated to 80 °C overnight.  The mixture was filtered over Ceilite, washed with 
EtOAc (20 mL) and concentrated in vacuo to provide 1-benzyl-4-(3-bromo-5-
methylphenyl)piperazine (2.6 g, 76%) as a brown oil.  
1
H NMR (CDCl3, 400 MHz): δ 7.35 (s. 2H), 
7.33 (d, J = 2.8 Hz, 2H), 7.31–7.27 (m, 1H), 6.83 (s, 1H), 6.79 (s, 1H), 6.62 (s, 1H), 3.55 (s, 2H), 
3.17 (t, J = 4.8 Hz, 4H), 2.57 (t, J = 4.8 Hz, 4H), 2.26 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 
152.6, 140.6, 138.1, 131.1, 129.3, 128.5, 127.3, 123.1, 116.0, 115.4, 63.2, 53.1, 48.9, 21.7;  High-
resolution ms (ESI, positive ion mode): calcd. for C18H21BrN2 (M + 1)
+
, m/z 345.0966; Found m/z 
345.0976.   
1-Benzyl-4-[3-(3-furyl)-5-methylphenyl]piperazine (74, EAR-II-178).  A mixture of a 3-
furanboronic acid (0.08 g, 0.72 mmol), 1-benzyl-4-(3-bromo-5-methylphenyl)piperazine (71, 0.16 
g, 0.47 mmol), tetrakis(triphenylphosphine)palladium (0.04 g, 0.03 mmol), and potassium 
carbonate (0.19 g, 1.41 mmol) in dimethylformamide (4.0 mL) and water (0.4 mL) were combined 
in a sealed tube, degassed with nitrogen gas and allowed to stir at 80 °C overnight.   The mixture 
was cooled to room temperature and filtered through Celite™, washed with ethyl acetate (20 mL), 
and evaporated to provide crude residues.  The crude residues were purified on a chromatotron 
with EMD 60PF254 silica gel eluting with hexanes/diethyl ether (80:20 for 250 mL) to provide 1-
benzyl-4-(3-(3-furyl)-5-methylphenyl) (74, 51.7 mg, 33%) as a clear colorless oil.  
1
H NMR 
(CDCl3, 400 MHz): δ 7.73 (t, J = 1.6 Hz, 1H), 7.49 (t, J = 1.6 Hz, 1H), 7.43–7.37 (m, 4H), 7.34–
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7.28 (m, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 6.71 (q, J = 1.6 Hz, 2H), 3.63 (s, 2H), 3.27 (t, J = 4H), 
2.67 (t, J = 4H), 2.38 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 152.1, 143.5, 139.3, 138.6, 138.1, 
133.2, 129.3, 128.4, 127.3, 127.1, 118.7, 115.9, 111.2, 109.2, 63.2, 53.3, 49.5, 21.9;  High-
resolution ms (ESI, positive ion mode): calcd. for C22H24N2O (M + 1)
+
, m/z 333.1967; Found m/z 
333.1952.  A hydrobromide salt: a white solid, mp 220 – 224 °C dec.   Anal Calcd. for C22H24N2O : 
C, 53.46; H, 5.30; N, 5.67. Found: C, 54.43; H, 5.51; N, 5.51.      
 
5.6 Synthesis of Pyridines 
 
4-Hydroxy-6-methylpyridin-2(1H)-one (76, EAR-II-130).  Ammonium hydroxide (11.3 mL) 
was added to a mixture of 4-hydroxy-6-methyl-2H-pyran-2-one (75, 11.3 g, 89.6 mmol) in ethanol 
(28.2 mL). The mixture was stirred at 130 °C overnight, then cooled to room temperature and 
concentrated in vacuo to yield 4-hydroxy-6-methylpyridin-2(1H)-one (76, 11.0 g, >99%).  
1
H 
NMR (CDCl3, 400 MHz): δ 5.59 (d, J = 2.4 Hz, 1H), 5.33 (d, J = 2.4 Hz, 1H), 3.43 (bs, 1H), 2.07 
(s, 3H). 
2,4-Dibromo-6-methylpyridine (77, EAR-II-133). 4-Hydroxy-6-methylpyridin-2(1H)-one (76, 
2.0 g, 16.1 mmol) was combined with phosphorous tribromide (5.6 g, 20.9 mmol) in a sealed tube 
and the mixture was heated at 190 °C for 5 h.  The mixture was poured over ice and allowed to 
warm to room temperature overnight.  Extracted mixture with dichloromethane (3 × 300 mL), 
dried (MgSO4), filtered and concentrated in vacuo to provide 2,4-dibromo-6-methylpyridine (75, 
2.0 g, 9%).   
1
H NMR (CDCl3, 400 MHz): δ 7.52 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 1.2 Hz, 1H), 2.55 
(s, 3H).  
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1-(4-Bromo-6-methylpyridin-2-yl)-4-methylpiperazine (78, EAR-II-145).  2,4-Dibromo-6-
methylpyridine (77, 2.67 g, 10.6 mmol), N-methylpiperazine (1.1 mL, 10.6 mmol), 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 0.49 g, 0.79 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (0.48 g, 0.53 mmol) and sodium tert-butoxide (1.2 g, 
12.7 mmol) in toluene (50.0 mL) were combined in a sealed tube and heated to 80 °C overnight.  
The mixture was filtered over Ceilite, washed with EtOAc (20 mL) and concentrated in vacuo to 
provide 1-(4-bromo-6-methylpyridin-2-yl)-4-methylpiperazine (78, 0.22 g, 8%) as a brown oil.  
1
H 
NMR (CDCl3, 400 MHz): δ 6.64 (s, 1H), 6.59 (s, 1H), 3.54 (t, J = 4.8 Hz, 4H), 2.49 (t, J = 4.8 Hz, 
4H), 2.35 (s, 3H), 2.33 (s, 3H). 
General Procedure for Synthesis of Compounds 79 – 81.  A mixture of a boronic acid (3-
furanboronic acid, 2-furanboronic acid or 3-thiopheneboronic acid) (0.03 g, 0.55 mmol), 1-(4-
bromo-6-methylpyridin-2-yl)-4-methylpiperazine (78, 0.10 g, 0.37 mmol), 
tetrakis(triphenylphosphine)palladium (0.03 g, 0.03 mmol), and potassium carbonate (0.17 g, 1.1 
mmol) in dimethylformamide (4.0 mL) and water (0.3 mL) were combined in a sealed tube, 
degassed with nitrogen and stirred at 90 °C overnight.   The mixture was cooled to room 
temperature and filtered through Celite™, washed with ethyl acetate (20 mL).  The filtrate was 
washed with water (3 × 25 mL) and brine (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo to provide crude residue.  The crude residue was purified on a chromatotron with EMD 
60PF254 silica gel eluting with hexanes/diethyl ether (80:20 over 200 mL, 1:1 over 150 mL, and 
finally 1:1 (with 5% methanol) for 200 mL) to provide pure 79 – 81. 
1-(4-(3-Furyl)-6-methylpyridin-2-yl)-4-methylpiperazine (79, EAR-II-157(2)). This compound 
was obtained as a clear colorless oil in 31% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.79 (s, 1H), 
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7.48 (s, 1H), 6.69 (s, 1H), 6.62 (s, 1H), 6.51 (s, 1H), 3.60 (t, J = 4.8 Hz, 4H), 2.55 (t, J = 4.8 Hz, 
4H), 2.42 (s, 3H), 2.36 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 157.5, 144.0, 141.8, 140.0, 128.7, 
125.6, 110.5, 108.8, 100.6, 55.1, 46.4, 45.5, 24.8;  High-resolution ms (ESI, positive ion mode): 
calcd. for C15H19N2O (M + 1)
+
, m/z 258.1606; Found m/z 258.1598. A hydrobromide salt:  a white 
solid, mp 150 – 152 °C.  Anal Calcd. for C15H19N3O•HBr, 0.5H2O: C, 51.88; H, 6.10; N, 12.10. 
Found: C,51.90; H, 6.50; N, 12.06.      
1-Methyl-4-(6-methyl-4-(2-thienyl)pyridine-2-yl)piperazine (80, EAR-II-158(8)). This 
compound was obtained as a clear colorless oil in 4% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.41 
(d, J = 3.2 Hz, 1H), 7.34 (d, J = 4.8 Hz, 1H), 7.09 (t, J = 3.6 Hz, 1H), 6.74 (s, 1H), 6.63 (s, 1H), 
3.61 (t, J = 4.8 Hz, 4H), 2.55 (J = 4.8 Hz, 4H), 2.43 (s, 3H), 2.36 (s, 3H).  A hydrobromide salt: a 
white solid, mp 132 – 134 °C.  Anal Calcd. for C15H19N3S•HBr: C, 50.85; H, 5.69; N, 11.86. 
Found: C,51.10; H, 5.69; N, 11.53.      
1-(4-(2-Furyl)-6-methylpyridin-2-yl)-4-methylpiperazine (81, EAR-II-166(8)). This compound 
was obtained as a clear colorless oil in 7.2% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.47 (t, J = 1.2 
Hz, 1H), 6.75 (t, J = 1.6 Hz, 2H), 6.72 (s, 1H), 6.47 (q, J = 3.2 Hz, 1H), 3.62 (t, J = 4.8 Hz, 4H), 
2.54 (t, J = 4.8 Hz, 4H), 2.41 (s, 3H), 2.35 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 159.9, 157.5, 
152.8, 143.0, 139.4, 111.9, 108.0, 107.7, 98.2, 55.0, 46.2, 45.3, 24.8;  High-resolution ms (ESI, 
positive ion mode): calcd. for C15H19N3O (M + 1)
+
, m/z 258.1606; Found m/z 258.1628. A 
hydrobromide salt: a white solid, mp 148 – 150 °C.  Anal Calcd. for C15H19N3O•HBr, H2O: C, 
50.57; H, 6.22; N, 11.79. Found: C, 50.41; H, 6.42; N, 11.39.      
2,6-Dibromo-4-methylpyridine (83, EAR-II-179). A Mixture of 4-methylpyridine-2,6-diol (82, 
5.0 g, 39.9 mmol) and phosphorous tribromide (4.9 mL, 51.9 mmol) in a sealed tube was heated at 
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190 °C overnight.  The mixture was poured over ice and allowed to warm to room temperature, 
then  extracted with dichloromethane (3 × 300 mL), dried (MgSO4), filtered and concentrated in 
vacuo to provide 2,6-dibromo-4-methylpyridine (83, 1.65 g, 16%).   
1
H NMR (CDCl3, 400 MHz): 
δ 57.60 (s, 2H), 2.30 (s, 3H). 
1-(6-Bromo-4-methylpyridin-2-yl)-4-methylpiperazine (84, EAR-II-184).  A mixture of 2,6-
dibromo-4-methylpyridine (83, 1.36 g, 5.4 mmol), N-methylpiperazine (0.60 mL, 5.4 mmol), 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 0.25 g, 0.40 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (0.25 g, 0.27 mmol) and sodium tert-butoxide (0.62 g, 
6.5 mmol) in toluene (15.0 mL) was heated to 80 °C in a sealed tube overnight.  The mixture was 
filtered over Ceilite, washed with EtOAc (20 mL) and concentrated in vacuo to provide 1-(6-
bromo-4-methylpyridin-2-yl)-4-methylpiperazine (84, 0.37 g, 26%) as a brown oil.  The crude 
product was purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/diethyl 
ether (80:20 over 200 mL, 1:1 over 150 mL, and finally 1:1 (with 5% methanol) for 200 mL) to 
provide pure 84.  
1
H NMR (CDCl3, 400 MHz): δ 6.61 (s, 1H), 6.32 (s, 1H), 3.54 (t, J = 4.8 Hz, 
4H), 2.49 (t, J = 4.8 Hz, 4H), 2.33 (s, 3H), 2.21 (s, 3H).  
General Procedure for the Synthesis of Compounds 85 – 87.  A mixture of a boronic acid (3-
furanboronic acid, 3-thipheneboronic acid, or 2-thiopheneboronic acid) (0.11 g, 1.02 mmol), 1-(6-
bromo-4-methylpyridin-2-yl)-4-methylpiperazine (84, 0.11 g, 0.68 mmol), 
tetrakis(triphenylphosphine)palladium (0.07 g, 0.05 mmol), potassium carbonate (0.28 g, 2.04 
mmol) in dimethylformamide (4.0 mL) and water (0.5 mL) in a sealed tube was degassed with 
nitrogen and stirred at 85 °C overnight.   The mixture was cooled to room temperature and filtered 
through Celite™, washed with ethyl acetate (20 mL).  The filtrate was washed with water (3 × 25 
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mL) and brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo.  The residue was 
purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/diethyl ether (80:20 
over 200 mL, 1:1 over 150 mL, and finally 1:1 (with 5% methanol) for 200 mL) to provide pure 85 
– 87. 
1-(6-(2-Furyl)-4-methylpyridin-2-yl)-4-methylpiperazine (85, EAR-III-2(2)). This compound 
was obtained as a clear colorless solid in 16% yield, mp 150 – 152 °C.  1H NMR (CDCl3, 400 
MHz): δ 7.95 (q, J = 1.6 Hz, 1H), 7.43 (t, J = 2.0 Hz, 1H), 6.83 (q, J = 1.6 Hz, 1H), 6.67 (s, 1H), 
6.35 (s, 1H), 3.60 (t, J = 4.8 Hz, 4H), 2.53 (t, J = 4.8 Hz, 4H), 2.35 (s, 3H), 2.28 (s, 3H); High-
resolution ms (ESI, positive ion mode): calcd. for C15H19N2O (M + 1)
+
, m/z 258.1606; Found m/z 
258.1608. Anal Calcd. for C15H19N3O•2HBr, H2O: C, 41.21; H, 5.30; N, 9.61. Found: C, 40.86; H, 
5.23; N, 9.76.      
1-Methyl-4-(4-methyl-6-(3-thienyl)pyridine-2-yl)piperazine (86, EAR-III-1). This compound 
was obtained as a clear colorless oil in 32% yield (60 mg).  
1
H NMR (CDCl3, 400 MHz): δ 7.83 (d, 
J = 2.0 Hz, 1H), 7.61 (d, J = 4.8 Hz, 1H), 7.32 (t, J = 4.8 Hz, 1H), 6.83 (s, 1H), 6.38 (s, 1H), 3.62 
(t, J = 4.8 Hz, 4H), 2.53 (t, J = 4.8 Hz, 4H), 2.34 (s, 3H), 2.29 (s, 3H); 
13
C NMR (CDCl3, 400 
MHz):  δ 159.4, 151.2, 148.9, 143.0, 126.4, 125.5, 122.8, 111.2, 105.7, 55.0, 46.3, 45.2, 21.5; 
High-resolution ms (ESI, positive ion mode): calcd. for C15H19N3S (M + 1)
+
, m/z 274.1378; Found 
m/z 274.1385. A hydrobromide salt: a white solid, mp 132 – 134 °C.  Anal Calcd. for 
C15H19N3S•HBr, 1.5H2O : C, 47.25; H, 6.08; N, 11.02. Found: C,47.44; H, 6.04; N, 11.27.      
1-Methyl-4-(4-methyl-6-(2-thienyl)pyridine-2-yl)piperazine (87, EAR-II-183). This compound 
was obtained as a clear colorless oil in 25% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.50 (dd, J = 
3.6, 0.8 Hz, 1H), 7.30 (dd, J = 5.2, 1.2 Hz, 1H), 7.06–7.04 (m, 1H), 6.86 (s, 1H), 6.34 (s, 1H), 3.61 
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(t, J = 4.8 Hz, 4H), 2.53 (t, J = 4.8 Hz, 4H), 2.34 (s, 3H), 2.28 (s, 3H); 
13
C NMR (CDCl3, 400 
MHz):  δ 159.0, 150.2, 148.9, 146.2, 127.6, 126.5, 123.6, 109.5, 105.7, 54.9, 46.2, 45.0, 21.5;  
High-resolution ms (ESI, positive ion mode): calcd. for C15H19N3S (M + 1)
+
, m/z 274.1378; Found 
m/z 274.1398. A hydrobromide salt: a yellow solid, mp 148 – 150 °C.  Anal Calcd. for 
C15H19N3S•2HBr, H2O: C, 39.75; H, 5.11; N, 9.27. Found: C, 39.42; H, 5.03; N, 9.60.      
5.7 Synthesis of Flexible-Chain Linked Derivatives 
 
tert-Butyl piperazine-1-carboxylate (88, EAR-III-3(2)).  Di-tert-butyl dicarbonate (13.8 mL, 
58.0 mmol) in dichloromethane (50 mL) was added to a solution of piperazine (10.0 g, 116.0 
mmol) in dichloromethane (160 mL) at 0 °C.  The mixture was stirred for 2 h, warmed to room 
temperature and stirred overnight.  A white precipitate was filtered, and dissolved in saturated 
aqueous potassium carbonate, extracted with ether (2 × 40 mL) and concentrated to provide tert-
butyl-piperazine-1-carboxylate (88) as a white solid in 50% yield.  
1
H NMR (CDCl3, 400 MHz): δ 
3.38 (t, J = 4.8 Hz, 4H), 2.80 (t, J = 4.8 Hz, 4H), 1.71 (s, 1H), 1.46 (s, 9H). 
Synthesis of compounds 90 & 91.  3,5-Dibromotoluene (48, 1.0 g, 4.0 mmol) or 2,6-
dibromopyridine (89, 1.0 g, 4.2 mmol) was combined with 1-Boc-piperazine (0.74 g, 4.0 mmol), 
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 0.18 g, 0.30 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (0.18 g, 0.20 mmol) and sodium tert-butoxide (0.46 g, 
4.8 mmol) in toluene (10.0 mL).  The mixture was stirred in a sealed tube and heated to 90 °C 
overnight.  The mixture was filtered over Ceilite, washed with EtOAc (20 mL) and concentrated in 
vacuo to provide crude residues of 90 or 91.  The residues were purified on a chromatotron with 
EMD 60PF254 silica gel eluting with hexanes/diethyl ether (80:20 over 200 mL, 1:1 over 150 mL, 
and finally 1:1 (with 5% methanol) for 200 mL) to provide pure 90 or 91.    
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tert-Butyl 4-(3-bromo-5-methylphenyl)piperazine-1-carboxylate (90, EAR-III-4). This 
compound was obtained as brown oil in 55% yield.  
1
H NMR (CDCl3, 400 MHz): δ 6.83 (s, 2H), 
6.63 (s, 1H), 3.55 (t, J = 5.0 Hz, 4H), 3.11 (t, J = 5.0 Hz, 4H), 2.27 (s, 3H), 1.48 (s, 9H). 
tert-Butyl 4-(6-bromopyridine-2-yl)piperazine-1-carboxylate (91, EAR-III-7(3)). This 
compound was obtained as brown oil in 17% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.31 (t, J = 7.6 
Hz, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 3.52 (s, 8H), 1.48 (s, 9H). 
General procedure for Suzuki coupling to prepare 92 & 93.  A mixture of 3-furanboronic acid 
(0.36 g, 3.2 mmol), 90 or 91 (0.76 g, 2.2 mmol), tetrakis(triphenylphosphine)palladium (0.19 g, 
0.17 mmol), and potassium carbonate (0.89 g, 6.45 mmol) in N,N-dimethylformamide (15.0 mL) 
and water (1.5 mL) in a sealed tube was degassed with nitrogen and stirred at 80 °C overnight.   
The mixture was cooled to room temperature and filtered through Celite™, washed with ethyl 
acetate (20 mL).  The filtrate was washed with water (3 × 25 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo to provide crude residue 92 or 93.  The crude residue 
was purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/ether (80:20 
over 200 mL) to provide 92 or 93. 
tert-Butyl 4-[3-(3-furyl)--5-methylphenyl]piperazine-1-carboxylate (92, EAR-III-5).  This 
compound was obtained as yellow oil in 45% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.69 (s, 1H), 
7.45 (s, 1H), 6.85 (s, 2H), 6.67 (s, 2H), 3.59 (t, J = 4.8 Hz, 4H), 3.15 (t, J = 4.8 Hz, 4H), 2.34 (s, 
3H), 1.48 (s, 9H); 
13
C NMR (CDCl3, 400 MHz):  δ 154.9, 152.0, 143.6, 139.5, 138.7, 133.4, 126.9, 
119.4, 116.5, 111.8, 109.2, 80.1, 49.8, 28.6, 21.9;  High-resolution ms (ESI, positive ion mode): 
calcd. for C20H26N2O3 (M + 1)
+
, m/z 343.2022; Found m/z 343.2024. 
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tert-Butyl 4-[6-(3-furyl)pyridine-2-yl]piperazine-1-carboxylate (93, EAR-III-14).  This 
compound was obtained as clear colorless oil in 37% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.96 
(q, J = 1.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.45 (t, J = 1.6 Hz, 1H), 6.84–6.83 (m, 1H), 6.82 (s, 
1H), 6.52 (d, J = 8.4 Hz, 1H), 3.57 (s, 8H), 1.49 (s, 9H);  
13
C NMR (CDCl3, 400 MHz):  δ 159.0, 
155.0, 150.0, 143.6, 141.3, 138.3, 130.5, 127.7, 109.9, 108.9, 105.4, 80.1, 45.2, 28.6;  High-
resolution ms (ESI, positive ion mode): calcd. for C18H23N3O3 (M + 1)
+
, m/z 330.1818; Found m/z 
330.1804. 
General procedure for the deprotection of Boc protected piperazine to provide 94 and 95.  1-
Trifluoroacetic acid (1.0 mL) was added to a solution of tert-butyl-4-[3-(3-furyl)-5-
methylphenyl]piperazine-1-carboxylate (92, 0.32 g, 0.96 mmol) or tert-butyl 4-[6-(3-
furyl)pyridine-2-yl]piperazine-1-carboxylate (93) in dichloromethane (5.0 mL).  The reaction 
mixture was stirred for one hour, and then concentrated in vacuo.  A solution of cold saturated 
sodium bicarbonate was added slowly to the residue to the pH = 9.  The aqueous layer was washed 
with dichloromethane (2 × 15 mL), dried over magnesium sulfate, filtered and concentrated in 
vacuo to provide 94 or 95. 
1-[3-(3-Furyl)-5-methylphenyl]piperazine (94, EAR-III-9). This compound was obtained as 
brown oil in 56% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.68 (s, 1H), 7.43 (t, J = 1.2 Hz, 1H), 6.83 
(s, 2H), 6.66 (s, 2H), 3.72 (bs, 1H), 3.18 (t, J = 4.8 Hz, 4H), 3.05 (t, J = 4.8 Hz, 4H), 2.32 (s, 3H); 
13
C NMR (CDCl3, 400 MHz):  δ 152.2, 143.5, 139.3, 138.6, 133.2, 126.9, 119.0, 116.0, 111.3, 
109.1, 50.2, 45.8, 21.8;  High-resolution ms (ESI, positive ion mode): calcd. for C15H19N2O (M + 
1)
+
, m/z 243.1497; Found m/z 243.1501. 
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1-[6-(2-Furyl)pyridine-2-yl]piperazine (95, EAR-III-17). This compound was obtained as clear 
colorless oil in 70% yield.  
1
H NMR (CDCl3, 400 MHz): δ 7.95 (s, 1H), 7.49 (t, J = 7.6 Hz, 1H), 
7.44 (t, J = 2.0 Hz, 1H), 7.24 (bs, 1H), 6.86–6.82 (m, 2H), 6.50 (d, J = 8.4 Hz, 1H), 3.72 (t, J = 4.8 
Hz, 4H), 3.15 (t, J = 4.8 Hz, 4H). 
2-Chloro-4-(3-furyl)pyridine (97, EAR-III-6).  A mixture of 3-furanboronic acid (1.30 g, 12.3 
mmol), 4-bromo-2-chloropyridine (96, 2.0 g, 10.3 mmol), tetrakis(triphenylphosphine)palladium 
(0.95 g, 0.82 mmol), and potassium carbonate (4.2 g, 30.9 mmol) in N,N-dimethylformamide (25.0 
mL) and water (3.0 mL) in a sealed tube was degassed with nitrogen and stirred at 90 °C overnight.   
The mixture was cooled to room temperature and filtered through Celite™, washed with ethyl 
acetate (20 mL).  The filtrate was washed with water (3 × 25 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo to provide crude residue 97.  The crude product was 
purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/ether (80:20 over 
300 mL) to provide 2-chloro-4-(3-furyl)pyridine (97, 0.568 g, 31%) as a white solide, mp 98 – 100 
°C. 
1
H NMR (CDCl3, 400 MHz): δ 8.35 (d, J = 5.2 Hz, 1H), 7.89 (s, 1H), 7.53 (s, 1H), 7.40 (s, 
1H), 7.29 (dd, J = 5.2, 1.2 Hz, 1H), 6.72 (s, 1H). 
1-(4-(3-Furyl)pyridin-2yl)piperazine (99, EAR-III-15). 1-Boc-piperazine (88, 0.91 g, 4.8 mmol) 
was added to 2-chloro-4-(3-furyl)pyridine (97, 0.44 g, 2.44 mmol) in toluene (7.0 mL) in a sealed 
tube.  The mixture was stirred at 125 °C for three days, then concentrated, and the crude residue 
(98) was used in the next step without purification.  Trifluoroacetic acid (1.0 mL) was added to a 
mixture of tert-butyl 4-(4-(3-furyl)pyridin-2-yl)piperazine-1-carboxylate (98, 0.34 g, 1.0 mmol) in 
dichloromethane (5.0 mL). The mixture was stirred at room temperature for one hour, after which 
the mixture was concentrated in vacuo.  A solution of cold saturated sodium bicarbonate was 
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added slowly to the residue to the pH = 9.  The aqueous layer was washed with dichloromethane (2 
× 15 mL), dried over magnesium sulfate, filtered and concentrated in vacuo.  The residue was 
purified on a chromatotron with EMD 60PF254 silica gel eluting with hexanes/ether (80:20 over 
250 mL) to provide 1-(4-(furan-3-yl)pyridin-2-yl)piperazine (99, 0.17 g, 73% yield) as a brown 
solid; mp 100 – 102 °C.   1H NMR (CDCl3, 400 MHz): δ 8.18 (d, J = 5.2 Hz, 1H), 7.82 (s, 1H), 
7.51 (t, J = 5.2 Hz, 1H), 6.76 (dd, J = 5.2, 1.2 Hz, 1H), 6.72–6.71 (m, 2H), 3.62 (t, J = 5.2 Hz, 4H), 
4.11 (bs, 1H), 3.07 (t, J = 5.2 Hz, 4H). 
General procedure for the synthesis of compounds 100 – 108.  Triethylamine (0.02 mL, 0.21 
mmol) was added to a mixture of 94, 95 or  99 (0.035 g, 0.14 mmol), the alkylbromide (6-bromo-
N-(4-cyanobenzyl)hexanamide, (5-bromo-2-methylpentan-2-ylsulfonyl)benzene or 1-(4-
bromobutyl)indolin-2-one (0.21 mmol) in acetonitrile (4.0 mL).  The mixture was stirred at 60 °C 
overnight, and then concentrated.  The residue was dissolved in dichloromethane (15 mL), and the 
solution was washed with water (2 × 15 mL), dried (MgSO4), filtered and concentrated. The 
residue was purified on a chromatotron with EMD 60PF254 silica gel eluting with 
hexanes/ether/methanol (80:20 over 300 mL, then 50:50 (w/5% methanol) to provide 100 – 108. 
N-(4-Cyanobenzyl)-6-[4-(3-(3-furyl)-5-methylphenyl]piperazine-1-yl)hexanamide (100, EAR-
III-10). The free base was obtained as a white solid in 15% yield; mp  116 – 118 °C; 1H NMR 
(CDCl3):  δ 7.68 (s, 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.45 (t, J = 1.6 Hz, 1H), 7.37 (s, 1H), 7.35 (s, 
1H), 6.83 (d, J = 5.6 Hz, 2H), 6.66 (s, 2H), 6.05 (bs, 1H), 3.22 (t, J = 4.6 HZ, 4H), 2.61 (t, J = 4.6 
Hz, 4H), 2.41 (t, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.59 (t, J = 7.6 Hz, 2H), 1.74–1.67 (m, 2H), 1.61–
1.53 (m, 2H), 1.41–1.36 (m, 2H);  13C NMR (CDCl3):  δ 173.2, 151.9, 144.3, 143.6, 139.4, 138.6, 
133.2, 132.6, 128.3, 127.0, 118.9, 118.8, 115.8, 111.3, 111.1, 109.2, 58.5, 53.4, 49.3, 43.1, 36.5, 
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27.2, 26.6, 25.6, 21.9;  High-resolution MS (ESI, positive ion mode): calcd. for C29H34N4O2 (M
+
 + 
1), m/z 471.2760; found m/z 471.2774.  Anal. Calcd. for C29H34N4O2: C, 74.01; H, 7.28; N, 11.91. 
Found: C, 73.69; H, 7.20; N, 11.98. 
N-(4-Cyanobenzyl)-6-[4-(3-(3-furyl)pyridin-2-yl]piperazin-1-yl)hexanamide (101, EAR-III-
19). The free base was obtained as a yellow oil in 44% yield; 
1
H NMR for the free base (CDCl3):  δ 
7.95 (s, 1H), 7.60 (d, J = 6.8 HZ, 2H), 7.48 (t, J = 7.2 HZ, 1H), 7.45 (t, J = 5.2 Hz, 1H), 7.38 (d, J 
= 8.4 Hz, 2H), 6.84–6.82 (m, 2H), 6.51 (d, J = 8.4 HZ, 1H), 6.11 (bs, 1H), 4.49 (d, J = 6.4 Hz, 2H), 
3.66 (t, J = 4.6 Hz, 4H), 2.66 (t, J = 4.6 Hz, 4H), 2.48 (t, J = 7.4 Hz, 2H), 2.27 (t, J = 7.4 Hz, 2H), 
1.76–1.68 (m, 2H), 1.67–1.61 (m, 2H), 1.45–1.38 (m, 2H);  13C NMR for free base (CDCl3):  δ 
173.2, 159.1, 150.0, 144.3, 143.6, 141.3, 138.2, 132.6, 128.4, 127.8, 118.9, 111.4, 109.8, 108.9, 
105.2, 58.6, 53.1, 46.0, 45.0, 43.2, 36.5, 27.1, 25.6;  High-resolution MS (ESI, positive ion mode): 
calcd. for C27H31N5O2 (M
+
 + 1), m/z 458.2556; found m/z 458.2552.  A hydrobromide salt, brown 
wax, mp 35 – 37 °C. Anal. Calcd. for C27H31N5O2•2HBr,H2O: C, 50.88; H, 5.53; N, 10.99. Found: 
C, 51.03; H, 5.50; N, 11.11. 
N-(4-Cyanobenzyl)-6-(4-(4-(3-furyl)pyridin-2-yl)piperazin-1-yl)hexanamide (102, EAR-III-
16). The free base was obtained as a white solid in 38% yield; mp 103 – 105 °C; 1H NMR 
(CDCl3):  δ 8.17 (d, J = 5.2 Hz, 1H), 7.81 (s, 1H), 7.61 (dd, J = 6.4, 1.6 Hz, 2H), 7.49 (t, J = 1.6 
Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 6.74 (dd, J = 5.2, 1.2 Hz, 1H), 6.70 (s, 2H), 6.05 (bs, 1H), 4.49 
(t, J = 6.0 Hz, 2H), 3.58 (t, J = 4.8 Hz, 4H), 2.56 (t, J = 4.8 Hz, 4H), 2.40 (t, J = 7.4 Hz, 2H), 2.26 
(t, J = 7.4 Hz, 2H), 1.75–1.67 (m, 2H), 1.61–1.53 (m, 2H), 1.43 (m, 1.34 (m, 2H); 13C NMR 
(CDCl3):  δ 173.0, 160.1, 148.4, 144.1, 141.4, 140.0, 132.4, 128.2, 125.1, 118.7, 111.2, 111.0, 
112 
 
 
108.4, 103.4, 58.4, 53.0, 45.2, 43.0, 36.4, 27.1, 26.4, 25.4;  Anal. Calcd. for C27H31N5O2: C, 70.87; 
H, 6.83; N, 15.31. Found: C, 71.12; H, 6.99; N, 15.65. 
1-(3-(3-Furyl)-5-methylphenyl-4-(phenylsulfonyl)pentyl)piperazine (103, EAR-III-13).  The 
free base was obtained as a yellow oil in 40% yield; 
1
H NMR for the free base (CDCl3):  δ 7.88 
(dd, J = 7.6, 1.6 Hz, 2H), 7.68 (s, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.45 (t, J = 
1.6 Hz, 1H), 6.83 (d, J = 7.2 Hz, 2H), 6.66 (s, 2H), 3.21 (t, J = 4.8 Hz, 4H), 2.59 (t, J = 4.8 Hz, 
4H), 2.38 (t, J = 7.6 Hz, 2H), 2.33 (s, 3H), 1.77–1.73 (m, 2H), 1.67–1.57 (m, 2H), 1.31 (s, 6H);  
13
C NMR for free base (CDCl3):  δ 160.3, 151.9, 143.6, 139.4, 138.6, 135.7, 133.7, 133.2, 130.7, 
128.9, 127.1, 118.8, 115.9, 111.2, 109.3, 63.0, 58.8, 53.5, 49.4, 33.0, 21.9, 21.7, 21.1;  High-
resolution MS (ESI, positive ion mode): calcd. for C27H34N2O3S (M
+
 + 1), m/z 467.2368; found 
m/z 467.2384.  A hydrobromide salt; mp 200 – 203 °C dec. Anal. Calcd. for C27H34N2O3S 
•2HBr,H2O: C, 50.16; H, 5.92; N, 4.33. Found: C, 50.45; H, 5.88; N, 4.61. 
1-[6-(3-Furyl)pyridin-2-yl)-4-(4-methyl-4-(phenylsulfonyl)pentyl]piperazine (104, EAR-III-
20).  The free base was obtained as a clear colorless oil in 31% yield; 
1
H NMR for the free base 
(CDCl3):  δ 7.95 (s, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.65–7.63 (m, 1H), 7.55 (t, J = 8.0 Hz, 2H), 7.45 
(t, J = 1.8 Hz, 1H), 7.44 (s, 1H), 6.83 (dd, J = 8.0, 1.8 Hz, 2H), 6.51 (d, J = 8.4 Hz, 1H), 3.59 (t, J = 
4.8 Hz, 4H), 2.55 (t, J = 4.8 Hz, 4H), 2.38 (t, J = 7.2 Hz, 2H), 1.77–1.73 (m, 2H), 1.63–1.61 (m, 
2H), 1.31 (s, 6H); 
13
C NMR for free base (CDCl3):  δ 159.2, 149.9, 143.6, 141.2, 138.2, 135.7, 
133.7, 130.7, 128.9, 127.8, 109.7, 108.9, 105.2, 105.0, 63.0, 58.9, 53.2, 45.2, 33.0, 21.1, 21.0;  A 
hydrobromide salt; 230 – 232 °C. Anal. Calcd. for C25H31N3O3S •2HBr,H2O: C, 47.70; H, 5.50; N, 
6.40. Found: C, 47.40; H, 5.57; N, 6.63. 
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1-[4-(3-Furyl)pyridin-2-yl)-4-(4-methyl-4-(phenylsulfonyl)pentyl]piperazine (105, EAR-III-
18).  The free base was obtained as a clear colorless oil in 21% yield; 
1
H NMR for the free base 
(CDCl3):  δ 8.17 (d, J = 5.2 Hz, 1H), 7.89 (s, 1H), 7.87 (d, J = 1.2 Hz, 1H), 7.65 (t, J = 7.4 Hz, 1H), 
7.55 (t, J = 8.0 Hz, 2H), 7.49 (t, J = 1.2 Hz, 1H), 6.74 (dd, J = 5.2, 1.2 Hz, 1H), 6.70 (s, 2H), 3.57 
(t, J = 4.8 Hz, 4H), 2.55 (t, J = 4.8 Hz, 4H), 2.38 (t, J = 7.4 Hz, 2H), 1.81–1.73 (m, 2H), 1.63–1.56 
(m, 2H), 1.31 (s, 6H); 
13
C NMR for free base (CDCl3):  δ 160.3, 154.4, 148.6, 144.1, 141.5, 140.1, 
135.7, 133.7, 130.7, 128.9, 125.4, 111.1, 108.6, 103.6, 63.0, 58.9, 53.3, 45.4, 32.9, 21.7, 21.0;  
High-resolution MS (ESI, positive ion mode): calcd. for C27H31N3O3S (M
+
 + 1), m/z 454.2164; 
found m/z 454.2172.  A hydrobromide salt; mp 180 – 184 °C (dec). Anal. Calcd. for 
C27H31N3O3S•2HBr,H2O: C, 47.40; H, 5.57; N, 6.63. Found: C, 47.02; H, 5.39; N, 6.88. 
1-[4-(4-(3-(3-Furyl)-5-methylphenyl)piperazin-1-yl)butyl]indolin-2-one (106, EAR-III-21). 
The free base was obtained as a white solid in 33% yield; mp 110 – 113 °C dec; 1H NMR (CDCl3): 
δ       7.68 (s, 1H), 7.44 (t, J = 1.6 Hz, 1H), 7.25 (t, J = 8.0 Hz, 2H), 7.02 (t, J = 7.6 Hz, 1H), 6.85 (t, 
J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 2H), 6.66 (s, 2H), 3.75 (t, J = 7.2 Hz, 2H), 3.52 (s, 2H), 3.21 
(t, J = 4.8 Hz, 4H), 2.59 (t, J = 4.8 Hz, 4H), 2.33 (s, 3H), 1.78–1.72 (m, 2H), 1.65–1.59 (m, 2H); 
High-resolution MS (ESI, positive ion mode): calcd. for C27H31N3O2 (M
+
 + 1), m/z 430.2495; 
found m/z 430.2504.   A hydrobromide salt. Anal. Calcd. for C27H31N3O2•2HBr : C, 54.84; H, 5.62; 
N, 7.11. Found: C, 55.03; H, 5.61; N, 7.32. 
1-[4-(4-(6-(3-Furyl)pyridin-2-yl)piperazin-1-yl)butyl]indolin-2-one (107, EAR-III-23). The 
free base was obtained as a brown oil in 20% yield; mp 242 – 244 °C; 1H NMR (CDCl3): δ  7.96 
(s, 1H), 7.48–7.43 (m, 2H), 7.26 (t, J = 7.2 Hz, 2H), 7.02 (t, J = 7.6 Hz, 1H), 6.87–6.79 (m, 3H), 
6.50 (d, J = 8.4 Hz, 1H), 3.75 (t, J = 6.8 Hz, 2H), 3.59 (t, J = 4.8 Hz, 4H), 3.52 (s, 2H), 2.55 (t, J = 
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4.8 Hz, 4H), 2.43 (t, J = 7.2 Hz, 2H), 1.78–1.71 (m, 2H), 1.65–1.60 (m, 2H);  High-resolution MS 
(ESI, positive ion mode): calcd. for C25H28N4O2 (M
+
 + 1), m/z 417.2291; found m/z 417.2288.   A 
hydrobromide salt. Anal. Calcd. for C25H28N4O2•2HBr, H2O : C, 50.35; H, 5.41; N, 9.39. Found: C, 
49.96; H, 5.52; N, 9.02. 
1-[4-(4-(4-(3-Furyl)pyridin-2-yl)piperazin-1-yl)butyl]indolin-2-one (108, EAR-III-22(2)). The 
free base was obtained as a white solid in 42% yield; mp 99 – 101 °C; 1H NMR (CDCl3):  δ 8.19 
(d, J = 5.2 Hz, 1H), 7.83 (t, J = 1.2 Hz, 1H), 7.51 (t, J = 1.6 Hz, 1H), 7.28 (t, J = 7.6 HZ, 2H), 7.04 
(t, J = 7.6 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.74 (dd, J = 5.2, 1.2 Hz, 1H), 6.72 (s, 2H), 3.77 (t, J = 
7.2 Hz, 2H), 3.60 (t, J = 4.8 Hz, 4H), 3.54 (s, 2H), 2.58 (t, J = 4.8 Hz, 4H), 2.45 (t, J = 7.2 Hz, 2H), 
1.80–1.73 (m, 2H), 1.68–1.60 (m, 2H); 13C NMR (CDCl3):  δ 175.2, 160.3, 148.6, 144.7, 144.1, 
141.5, 140.1, 128.0, 125.4, 124.8, 124.6, 122.3, 111.1, 108.7, 108.5, 103.6, 58.1, 53.2, 45.4, 39.9, 
36.0, 25.4, 24.3; High-resolution MS (ESI, positive ion mode): calcd. for C25H28N4O2 (M
+
 + 1), 
m/z 417.2291; found m/z 417.2289;  Anal. Calcd. for C25H28N4O2, 2H2O: C, 66.35; H, 7.13; N, 
12.38. Found: C, 66.32; H, 6.95; N, 12.41. 
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